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 ABBREVIATIONS 
 
4HC = 4-hydroxtycyclophosphamide 
4HT = 4-hydroxytamoxifen 
ALDH-1 = aldehyde dehydrogenase-1  
BCRP-1 = breast cancer resistance protein-1 
BRCA 1/2 = breast cancer 1/2 gene 
BSA = bovine serum albumin 
CA-125 = cancer antigen-125 
CARC = carcinogens-treated animals  
CHOP = cyclophosphamide + doxorubicin + prednisone + vincristine  
CMF = cyclophosphamide + methotrexate + fluorouracil 
CONT = vehicle-treated animals  
COX-2 = cyclooxygenase-2  
Cy = cyclophosphamide 
DCIS = ductal carcinoma in situ  
DAB = diaminobenzidine  
DMBA = 7, 12 dimethylbenza[α]anthracene  
DMEM/F-12 = Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (1:1) 
DMSO = Dimethyl sulfoxide 
E2 = 17β-estradiol  
EGCG = epigallocatechin 3-gallate 
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 EOC = epithelial ovarian cancer  
ER = estrogen receptor  
FSH = follicular stimulating hormone 
GnRH = gonadotropin releasing hormone 
hCG = human chorionic gonadotropin 
HEPES = 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
H&E = hematoxylin and eosin 
HER-2/neu = human Epidermal growth factor Receptor 2 
IOD = Integrated Optical Density  
LCIS = lobular carcinoma in situ 
LH = luteinizing hormone 
MAC = mammary adenocarcinoma  
MEM EAA = Minimal Essential Medium Essential Amino Acids 
MEM NEAA = Minimal Essential Medium Non-essential Amino acids 
MMTV = Mouse mammary tumor virus 
MNU = N-Nitroso-N-methylurea 
MRECM1 = Modified Rat Embryo Culture Medium 
NSAIDs = Non-steroidal anti-inflammatory drugs 
PFA = paraformaldehyde 
PR = progesterone receptor 
RR = relative risk 
SERMs = selective estrogen receptor modulators 
 8
 TAM = tamoxifen 
TBST = Tris-Buffer Saline with Tween-20 
Tris = tris(hydroxymethyl)aminomethane 
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 ABSTRACT 
Women at high risk for breast cancer are often also at high risk for ovarian cancer, 
reflecting similar risk factors and suggesting intertwined disease pathways and 
common prevention targets.  A novel strategy to overcome obstacles in preventing 
ovarian neoplasia (low incidence, lack of specific disease markers, and difficulties in 
tissue sampling), the deadliest gynecologic cancer, may be to develop a prevention 
strategy that targets breast and ovarian cancer simultaneously.  Tamoxifen, a selective 
estrogen receptor modulator, reduces hormone responsive breast cancer risk by 50% 
but its effects on risk of ovarian cancer, also hormonal responsive, are unclear.  The 
goals of this work were to 1) develop and characterize a preclinical model of 
concurrent breast and ovarian cancer and 2) use this dual cancer model to examine the 
efficacy of tamoxifen to prevent both breast and ovarian cancer.  Mammary 
carcinogens [7,12-dimethylbenz[α]anthracene (DMBA), N-methyl-N-nitrosourea and 
estradiol (E2)] were tested separately in combination with local ovarian DMBA 
administration to determine the best combined treatment to induce mammary and 
ovarian cancer concurrently and effectively in the rat.  Results showed that systemic 
E2 and ovarian DMBA promoted the highest incidence of dysplasia in the mammary 
gland and ovary and elevated levels of mammary Ki-67 and cyclooxygenase 2 (COX-
2) mimicking the human disease.  Next, the ability of tamoxifen to prevent mammary 
and ovarian cancer simultaneously was evaluated.  Tamoxifen which inhibited 
mammary carcinogenesis and normalized levels of Ki-67 and COX-2, had no effect 
on (neither accelerated nor inhibited) ovarian cancer progression.  In addition, 
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 carcinogen treatment increased levels of stem cell markers, Oct-4 and aldehyde 
dehydrogenase-1, in the mammary gland; interestingly, this expansion was not 
reversed by tamoxifen.  Intriguingly, while examining ovaries from this study, we 
serendipitously discovered an apparent protective effect of tamoxifen against DMBA-
induced follicular destruction and this effect was further investigated.  Chemotherapy 
and environmental toxicants (e.g. DMBA) deplete ovarian follicles and often lead to 
accelerated ovarian aging and premature ovarian failure; however, there is no 
established treatment that can protect the ovary from these toxic insults.  In vivo, rats 
were treated with tamoxifen and DMBA or cyclophosphamide (the most ovotoxic 
chemotherapy) and total numbers of follicles in the ovary were determined.  In vitro, 
ovarian organ culture and oocyte culture were carried out to examine local effects of 
tamoxifen on DMBA-induced follicle loss and doxorubicin-induced oocyte 
fragmentation, respectively.  We demonstrated for the first time that tamoxifen 
protects ovarian follicles against not only DMBA- but also chemotherapy 
(cyclophosphamide and doxorubicin)-induced ovarian damage.  Clinically, tamoxifen 
has already been tested for safe use as an adjuvant therapy for several cancers; 
therefore, if translated into clinical use, these results may have immediate impact on 
options for fertility preservation and quality of life in young female cancer patients 
undergoing chemotherapy.  The long term goals of this work are to 1) use the dual 
cancer model to screen for promising agents that decrease risks for both breast and 
ovarian cancer and 2) examine the mechanism by which tamoxifen inhibits toxicant-
induced ovarian follicle loss.   
 11
  
 
 
 
 
CHAPTER I 
 
 
 
 
INTRODUCTION 
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 Breast and ovarian cancer and their risk factors:   
Breast cancer affects 1 in 8 women in the United States and causes over 40,000 
deaths annually [1].  Ovarian cancer affects only 1 in 70 women; however, it results 
in almost half as many fatalities as those of breast cancer and is the leading cause of 
death for all gynecological malignancies [1].  This high mortality rate of ovarian 
cancer is largely due to a lack of diagnostic tools for detection during treatable stages, 
indicating the need for prevention strategies.  However, ovarian cancer prevention 
trials are seldomly attempted due to low incidence, lack of disease biomarkers and 
difficulties in sampling the ovary [2].  Interestingly, women at high risk for breast 
cancer are often also at high risk for ovarian cancer [3], reflecting common risk 
factors and intertwined disease pathways [4,5].   
Over 90% of all breast and ovarian cancer cases are sporadic while 5-10% are 
familial caused by germline mutation in BRCA1 or BRCA2 genes [4,6].  BRCA1/2 
mutations increase lifetime risks of breast and ovarian cancer from 12% and 1.4% to 
approximately 60-80% and 20-40%, respectively [7-10].  Nulliparity and prolonged 
lifetime exposure to estrogen (i.e. early menarche and late menopause as well as 
hormone replacement therapy) are associated with elevated risks for both breast and 
ovarian cancer, while early age at first childbirth and  multiple pregnancies decrease 
their incidences [11-13].  Oral contraceptive usage has been shown to have a 
protective role against ovarian cancer but with a less clear role in breast cancer risk 
[14-16].  The similarity between risk factors for breast and ovarian cancer suggest 
their interdependent disease pathways and possible common prevention targets.  A 
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 logical and feasible approach to ovarian cancer chemoprevention may be the 
development of breast cancer prevention drugs that simultaneously decrease ovarian 
cancer risk.   
 
Histopathology of breast cancer:   
Ductal carcinoma, the most common type of breast cancer, is derived from the 
epithelial lining of milk ducts and accounts for approximately 80% of all breast 
cancer cases in women [17,18].  Lobular carcinoma is derived from alveoli and 
represents the majority of non-ductal breast carcinomas [17,18].  Other types of breast 
cancer, while less common, include mucinous (3%; mucus-producing cells), 
medullary (2%; central breast tissue) and tubular (2%; ductal cells) [19].  Early 
changes of ductal carcinoma include cellular hyperplasia, hyperplasia with atypia and 
carcinoma in situ and each of these histological stages is associated with an elevated 
risk for breast cancer (Figure 1) [20-25]. 
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 Current breast cancer chemoprevention:   
The average woman has a 12% lifetime risk for breast cancer and currently about a 
75-80% chance of cure once the cancer has developed, due largely to early detection 
as well as advances in prevention therapy [26].  Indeed, breast cancer 
chemoprevention trials are facilitated by minimally invasive techniques to sample 
breast tissue and the availability of a number of surrogate biomarkers to evaluate 
prevention drugs in phase II trials, as well as the high incidence of this disease in 
phase III trials [27-29].  Candidates for breast cancer prevention include selective 
estrogen receptor modulators (SERMs), aromatase inhibitors, COX-2 inhibitors, 
retinoids, and natural compounds such as resveratrol, epigallocatechin-3-gallate 
(EGCG, found in green tea), etc.  A list of detailed current clinical trials for breast 
cancer prevention is summarized in table I.   
Table I:  Examples of current clinical trials for breast cancer prevention [30] 
Prevention agent tested Drug class Phase Patient population 
Exemestane Aromatase inhibitor III Postmenopausal  
Dietary soy Natural compound III Premenopausal  
Letrozole  Aromatase inhibitor III Postmenopausal  
hCG analog  hCG  III Age 30-75 
Deslorelin GnRH analog II Age 21-48 
Grape Seed Extract Natural compound I Age 40-75 
Green Tea Extract (EGCG) Natural compound I Age 21-65 
White Button Mushroom Extract Natural compound I Age 21 and over 
 
Currently, the SERMs tamoxifen and raloxifene have been shown to reduce 
breast cancer risk by roughly 50% and are the only approved agents for use in high 
risk women to prevent breast cancer.  Following results of the National Surgical 
Adjuvant Breast and Bowel Project P2 trial, it appears likely that tamoxifen and 
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 raloxifene will be the mainstay for breast cancer prevention for pre- and 
postmenopausal women for at least the next decade [31].  However, despite some 
known effects of SERMs on ovarian function in premenopausal females [32,33], little 
attention has been paid to the possible ovarian effects of breast cancer 
chemoprevention and potential risk for ovarian cancer.   
 
Histopathology of ovarian cancer:  
Classification of ovarian cancer is determined by the cell type of tumor origin (Table 
II).  Epithelial ovarian cancer (EOC) is the most common type of ovarian cancer and 
accounts for 90% of all cases.  EOC is derived from the surface epithelium consisting 
of a single cell layer that covers the entire ovary (Fig. 2).  Based on their tissue types, 
ovarian epithelial tumors can be further divided into a number of subtypes with 
serous EOC being the most prevalent (Table III).  The etiology of ovarian cancer is 
still unknown; however, studies have associated its cause with “incessant ovulation.”  
Table II:  Histologic classification of ovarian cancer 
Ovarian cancer types Tumor origin Prevalence 
Epithelial ovarian tumor Surface epithelial 85-90% 
Sex cord-stromal tumor Germ cells  5-7% 
Germ cell tumor Granulosa/Theca 5% 
 
Table III:  Different types of epithelial ovarian cancer (EOC) 
EOC subtypes Tumor cell type Prevalence 
Serous  Fallopian tube epithelium 40% 
Endometrioid  Proliferative endometrium 20% 
Mucinous GI tract or endocervical epithelium 1% 
Clear cell Gestational endometrium 6% 
Borderline Mixed 10-15% 
Undifferentiated Poorly differentiated  15% 
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 This hypothesis states that constant proliferation and DNA repair at the ovulatory 
rupture site may be an initiating factor for common ovarian cancers, reflecting 
preneoplastic changes of the ovary, such as surface epithelial hyperplasia and 
formation of surface papilloma and epithelial inclusion cysts (Fig. 2) [34-36].   
Studies have also suggested the involvement of gonadotropins in ovarian 
cancer etiology [37].  The “gonadotropin hypothesis” reasons that atypical 
entrapment of ovarian surface epithelium (inclusion cysts or epithelial invagination) 
within the ovarian stroma will lead to proliferation and malignant transformation 
under the influence of excessive follicle stimulating hormone (FSH) and luteinizing 
hormone (LH) [38,39].  Other factors such as p53 mutation, estrogen, progesterone 
and androgen levels have also been associated with ovarian cancer risk [38].  While 
several hypotheses exist for the cause of ovarian cancer, the etiology is most likely a 
combination of multiple factors.  
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 Current ovarian cancer chemoprevention: 
A woman’s lifetime risk of developing ovarian cancer is less than 2%, but it is the 
deadliest gynecological cancer with 5 year survival of less than 25% for Stages III 
and IV where over 75% of cases are detected [40,41].  This is primarily because 
ovarian cancer usually remains clinically silent and inaccessible diagnostically until it 
is beyond treatable stages, suggesting a need for prevention strategies. 
Apart from surgically removing the ovary, past candidates for ovarian cancer 
prevention include oral contraceptives, fenretinide and COX inhibitors.  Oral 
contraceptives have been shown to reduce risk of sporadic and familial ovarian cancer 
especially for longer duration of use [42].  The preventive effect of oral contraceptive 
use is, in part, due to inhibition of ovulation, a risk factor for ovarian cancer [43-46].  
Fenretinide, a vitamin A derivative, was found to decrease ovarian cancer risk as a 
secondary effect in a breast cancer prevention trial [47,48].  COX-1/2 are often 
overexpressed in ovarian tumors [49-52], and COX inhibitors were shown to be 
associated with a reduction in ovarian cancer risk in a pooled study examining the 
link between non-steroidal anti-inflammatory drugs (NSAIDs) and cancer  [53,54].  
However, the use of some COX inhibitors raises concerns including increased risk of 
heart attack and stroke and questions their use for cancer prevention [55].  Effects of 
SERMs on ovarian function and pathology have been reported [32,56];  in fact, both 
tamoxifen and raloxifene promote abnormal ovarian function (i.e. irregular menstrual 
cycle) and follicular cyst formation in the ovary, but their effect on ovarian cancer 
risk are still controversial [32,33,57,58]. 
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 Research in ovarian cancer prevention is sparse due in large part to a low 
incidence of the disease, delayed diagnosis, lack of ovarian cancer specific 
biomarkers, and difficulty in accessing ovarian tissue, leading to difficulties in 
conducting clinical trials even with promising preventive agents available.  A 
potential strategy for ovarian cancer prevention may be to develop prevention 
strategies targeting more common cancers, with selection of drugs that also protect 
against ovarian cancer.   
 
Dual cancer prevention:   
Breast and ovarian cancer have similar risk factors such as estrogen exposure, 
ovulation, nulliparity, obesity, family history as well as BRCA1/2 mutations and 
women at increased risk for one of these cancers are often also at risk for the other 
suggesting intertwined disease pathways and possible common targets for prevention 
[4,59].  Therefore, difficulties in preventing ovarian neoplasia may be overcome by a 
prevention strategy that targets breast and ovarian cancer simultaneously.  Indeed, 
successful human ovarian cancer chemoprevention has only been demonstrated 
incidentally during the course of breast cancer prevention trials (i.e. fenretinide); 
although results from this study showed a moderate preventive effect in 
premenopausal women while an opposite trend (elevated risk) in postmenopausal 
women [47,48].  Very few compounds have been tested for dual action against both 
cancers due in part to the lack of appropriate animal models that develop both 
diseases.  Although the effects of chemoprevention drugs can be tested separately in 
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 preclinical models, this approach ignores the intertwined etiologies of breast and 
ovarian cancer as well as potential synergism between effects in the breast and ovary 
of prevention drugs. 
 
Animal models for breast and ovarian cancer:  
Rats are the most frequently used animal model for breast cancer chemoprevention 
studies due to their shorter life span, plentiful tissue, and lack of the mouse mammary 
tumor virus (MMTV) which causes mammary tumors by a different etiology than the 
human disease.  Most common and well-established mammary cancer models used 
for prevention studies involve tumor induction by chemical carcinogens 7,12-
dimethylbenz[α]anthracene (DMBA), and N-methyl-N-nitrosourea (MNU) and the 
hormonal carcinogen E2 [60-63].  Common features of these models include high 
incidence of tumor induction, organ site specificity, tumors of ductal origin, and 
tumors that are hormone-dependent and have similar histology as the human disease.  
As demonstrated by Li and colleagues [62], one major advantage of using E2 as a 
mammary carcinogen over chemical carcinogens is that estrogen-induced tumors are 
highly aneuploid as is human breast cancer.  No commonly used rat model of EOC 
exists but one promising method is the direct application of DMBA to the ovarian 
surface epithelium, resulting in an approximate 30-50% occurrence of EOC following 
12 months of treatment [64-66].   
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 Common biomarkers for breast and ovarian cancer: 
Surrogate end point biomarkers vary with risk and response to prevention drugs [67].  
Common surrogate end point biomarkers for breast cancer include hormone receptors 
(ER and progesterone receptor, PR), Ki-67, human epidermal growth factor receptor-
2 (HER-2), and COX-2 [29,68-71].  While specific biomarkers for ovarian cancer are 
still being identified, currently, levels of serum cancer antigen-125 (CA-125), COX-
1/2, ER, PR, and Ki-67 are used to track disease progress, however, without enough 
sensitivity and specificity for early diagnoses [72-76].   
The estrogen, progesterone and ER pathway plays an important role in normal 
development as well as the pathophysiology of the breast and ovary.  Therefore, 
serum levels of estrogen and progesterone and their local receptor expression are 
critical in risk assessment, therapy and prognosis of breast and ovarian cancer 
[68,77,78].  Ki-67 is a nuclear antigen expressed by proliferating cells in all active 
phases (G1, S, G2 and M) of the cell cycle and absent in resting (G0 phase) cells [70].  
It is used routinely as a proliferation marker to measure human tumor growth [29,69].     
COX-2 expression is induced by growth factors as well as pro-inflammatory 
cytokines and elevated during the growth of various tumors [79].  In the breast, COX-
2 expression increases aromatase production by which cells resulting in an elevated 
local estrogen concentration. Overexpression of COX-2 is found in proliferative 
breast disease (hyperplasia), ductal carcinoma in situ/lobular carcinoma in situ 
(DCIS/LCIS), and invasive breast cancer [80].  In the ovary, COX-2 is involved in 
normal female reproductive functions such as ovulation, implantation and 
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 decidualization. However, COX-2 overexpression is often associated with ovarian 
neoplasia [49,50,81].  HER-2/neu belongs to the epidermal growth factor receptor 
family and is associated with cell growth and proliferation.  Overexpression of HER-
2 is found in 15-30% of breast cancer cases and corresponds to a higher nuclear grade 
and aneuploidy as well as a poorer prognosis of the disease [82,83]. 
CA-125, a serum biomarker, is useful for monitoring response to 
chemotherapy and detecting disease recurrence [84,85].  However, its low specificity 
and sensitivity have limited its use primarily to disease monitoring and it is usually 
used only in parallel with other cancer biomarkers [86].  Currently, identification of 
additional biomarkers specific to breast and ovarian cancer are still a top priority for 
early detection. 
 
Breast stem cells in breast cancer progression:   
The size of the stem cell pool in the breast has been suggested as an indicator of poor 
clinical outcome for breast cancer [87].  The existence of self-renewing, pluripotent 
stem cells have been demonstrated both in human breasts and rodent mammary 
glands [88,89]. In animal models, transplantation of enriched mammary stem cells 
into cleared mammary fat-pads causes regeneration of an entire functional gland [90-
92].  In the human breast, stem cells can be isolated and are characterized by their 
ability to divide and form mammospheres in culture as well as to reconstruct 
functionally normal breast tissues in a rodent model [88,93].  Studies have suggested 
that breast cancers are likely to emerge from inherited or acquired mutations in these 
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 breast stem cells [94-96].  Deregulation of cancer stem cells results in tumor growth 
and regrowth of refractory cancer cells following primary treatment.  Inability of 
chemotherapy agents to destroy deregulated stem cell populations has been suggested 
to be the reason for cancer recurrence, tumor regrowth and poor clinical outcome, 
indicating a need for new treatment strategies targeting stem cells [97]. 
 
Current breast stem cell markers:   
Potential markers for breast stem cells include Hoechst dye exclusion, protein 
expression of breast cancer resistance protein-1 (BCRP-1, membrane transporter 
responsible for Hoechst dye efflux), Oct-4, survivin and aldehyde dehydrogenase-1 
(ALDH-1).  BCRP-1 belongs to a family of drug-efflux protein pumps (ABC 
transporters) present in stem cells and is suggested to cause drug resistance in many 
types of cancer including breast [98,99].  Oct-4 is a transcriptional factor expressed 
by early embryo cells and germ cells and has been used to identify pluripotent cell 
populations [100,101].   Additionally, ALDH-1, an enzyme that is required for the 
conversion of retinol to retinoic acids, is highly enriched in hematopoietic stem cells 
and recently, researchers have suggested its presence in breast stem cells as well 
[102]. In the current study, expression of stem cell markers was examined during 
mammary carcinogenesis and in response to cancer chemoprevention therapy with 
tamoxifen. 
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 Tamoxifen:   
Tamoxifen, a selective estrogen receptor modulator (SERM), binds estrogen receptors 
competitively with endogenous estrogen and promotes estrogenic or anti-estrogenic 
activities in a tissue specific manner [103].  In the breast, tamoxifen blocks cell 
proliferation, has been shown to cause tumor regression and prevent tumor formation, 
and is the most widely prescribed drug for treatment and prevention of hormone-
dependent breast cancer [104].  Tamoxifen also antagonizes the effect of estrogen in 
the brain while agonizes estrogen’s action in the bone, uterus and cardiovascular 
system.  In the ovary, the role of tamoxifen is far less understood due to cellular 
complexity of the ovary.  In premenopausal women, tamoxifen has been suggested to 
promote abnormal ovarian function and cyst formation but its effect on ovarian 
cancer risk is still unclear [32,105].     
Tamoxifen and other SERMs have a complex and only partially understood 
mechanism of tissue specific activation or inhibition of estrogen signaling [106].  
This tissue specificity of SERMs is dependent upon 1) levels of endogenous 
estrogens, 2) local concentrations of ER α and β and their ratio, 3) estrogen receptor 
polymorphisms, 4) availability of ER coactivators (for estrogenic actions) or 
corepressors (for anti-estrogenic actions), and 5) activation of classical (or genomic) 
pathways or non-classical (dependent upon protein-protein interactions between ER 
complex and AP-1) pathways [106].  The impact of SERMs on ovarian estrogen 
signaling is particularly complex since any direct ovarian action is coupled with 
altered gonadotropin stimuli and estrogen feedback system in premenopausal females 
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 [107].  In cycling rats, SERMs increases gonadotropin secretions due to loss of 
hypothalamic estrogen feedback signaling and elevates local estrogen production in 
the ovary [108]. 
A single study examined the effect of prednisone or prednisone + tamoxifen in 
addition to standard chemotherapy on reproductive function in premenopausal breast 
cancer patients [109].  While, this study did not investigate the effect of tamoxifen on 
ovarian cancer risk, it showed that interestingly, the addition of tamoxifen was 
associated with a delayed amenorrhea; this is an interesting observation considering 
that amenorrhea is a common side effect of standard chemotherapy.   
 
Fertility in Female Cancer Patients: 
More than 100,000 women under the age of 45 are diagnosed with cancer each year 
in the United States.  Standard cancer chemotherapy and radiation therapy often cause 
immediate or eventual premature menopause and infertility [110,111].  Incidence of 
ovarian failure following cancer treatment varies widely with age and chemotherapy 
regimen, with advancing age and dose intensity and regimens including alkylating 
agents, particularly cyclophosphamide, predisposing to ovarian damage and infertility 
[112,113].  On average, 50-80% of patients receiving chemotherapy experience 
prolonged or permanent amenorrhea post-treatment [112,114].  Previously, this 
infertility and iatrogenic menopause was viewed by physicians and patients as an 
acceptable cost of curative chemotherapy and radiation regimens.  However, with 
early diagnosis, higher survival rate [115], and increased age for child bearing [116], 
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 cancer therapy-induced infertility has become a major survivorship issue.  The impact 
of cancer chemotherapy on reproductive health and fertility has only recently been 
appreciated and strategies to prevent such reproductive toxicity are urgently needed.    
 
Current options for fertility preservation:   
Embryo cryopreservation prior to cancer treatment is currently the only approved 
option for these patients, however, this technique has limitations.  Cryopreservation 
of embryos does not preserve ovarian function, requires several weeks to months, 
must be completed prior to cancer therapy, is applicable only to patients with a 
current partner and often fails due to poor embryo quality [117].  Experimental 
options for fertility preservation include ovarian or oocytic cryopreservation and 
GnRH agonist therapy [118,119].  Oocyte freezing also delays treatment and has little 
success to date due to fragility of the oocytic meiotic spindle and formation of ice 
crystals during freezing [117,120].  Ovarian tissue cryopreservation is surgically 
invasive, carries risk for possible cancer cell transmission, and causes ischemic 
damage to the ovary leading to poor oocyte viability [120].  Hypothalamic 
suppression with GnRH agonists is used in an effort to decrease the ovarian toxicity 
from cancer therapy by inducing a putatively protective hypogonadotropic 
hypogonadism [121].  GnRH agonist was shown to decrease cyclophosphamide-
induced ovarian toxicity in non-human primates [122].  Blumenfeld and colleagues 
have documented chemoprotective effects of GnRH suppression against infertility in 
women following chemotherapy for lupus and lymphoma [123,124].  However, other 
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 groups have not observed benefit from this controversial protocol [125].  In addition, 
treatment with GnRH agonists does not protect the ovary from radiation-induced 
ovotoxicity [126] and the interaction of GnRH modulation with chemotherapy in 
cancer cells is unknown.  Additional fertility preservation options for cancer patients 
are still needed. 
 
Animal models for the study of chemical-induced ovarian toxicity: 
Two of the most extensively studied ovotoxic agents in animal models are DMBA 
and cyclophosphamide.  DMBA, a polycyclic aromatic hydrocarbon, is commonly 
used in rodent models to induce a variety of cancers [64,127].  In addition to being a 
carcinogen, DMBA also destroys follicular reserve and causes ovarian failure 
[128,129].  While the mechanism by which DMBA targets and destroys follicles in 
the ovary is not entirely understood, many investigators have suggested that apoptosis 
plays a critical role [129,130].  Cyclophosphamide, also known as Cytoxan, is an 
alkylating agent that is commonly used as a part of standard regimen therapy for 
many malignancies including lymphomas, leukemia, and solid tumors [131,132].  
Cyclophosphamide is a prodrug that is converted in the liver into active metabolites, 
mainly 4-hydroxycyclophosphamide, which is further converted into its ultimate 
toxicant, phosphoramide mustard, that forms adduct with DNA leading to cell death 
[133].  Cyclophosphamide is considered to be the most ovotoxic cancer drug resulting 
in a high rate of ovarian failure in cancer patients [110,134].  In rodents, 
cyclophosphamide causes gonadal damage and sterility in a dose-, duration-, species-, 
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 and strain- dependent manner [135,136].  Doxorubicin, also known as Adriamycin, 
intercalates with DNA and inhibits helicases and topoisomerases and is another 
frequently studied chemotherapeutic agent known for its ovotoxicity [137].  Similar 
to DMBA-induced ovarian toxicity, cyclophosphamide and doxorubicin have been 
shown to target the ovary directly and cause atresia [138].  However, while some 
studies have shown that DMBA and doxorubicin delete ovarian follicles by elevating 
Bax protein and apoptosis in oocytes [129,137]; others have suggested that 
cyclophosphamide-induced follicle depletion is driven by apoptosis in oocyte 
supporting cells [138].  
 
Specific aims of this work: 
Women at high risk for breast cancer are often also at high risk for ovarian cancer [3], 
reflecting similar risk factors and suggesting intertwined disease pathways and 
common prevention targets [4].  A novel strategy to overcome obstacles in preventing 
ovarian cancer, the deadliest gynecologic malignancy, may be to develop a strategy 
that will simultaneously decrease risks for both breast and ovarian cancer.  Very few 
compounds have been tested for dual action against both cancers due in part to the 
lack of appropriate animal models that develop both diseases.  Tamoxifen, a SERM, 
reduces breast cancer risk by almost 50% but its effects on ovarian cancer risk are 
still unclear.  In testing tamoxifen for ovarian cancer prevention, we found that 
tamoxifen inhibits ovotoxicant-induced follicle loss in the ovary.  Chemotherapy and 
environmental toxicants such as DMBA deplete ovarian follicles leading to 
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 accelerated ovarian aging and premature ovarian failure.  To date, there is no 
established method that protects the ovary from the ovotoxic effect of environmental 
toxicants and chemotherapy.  Objectives of this study were to 1) develop and 
characterize a preclinical model that exhibits concurrent mammary and ovarian 
cancer, 2) test the effect of tamoxifen on the progression towards mammary and 
ovarian cancer using the dual cancer model, and 3) investigate the protective effect of 
tamoxifen against ovotoxic agents including DMBA and chemotherapy.  These 
objectives were investigated through the following aims: 
 
Aim 1:  Develop and characterize a rat model of simultaneous breast and 
ovarian cancer suitable for dual cancer prevention studies 
In this aim, three established mammary cancer carcinogen models (DMBA, MNU 
and E2) were combined with local ovarian DMBA administration to induce 
progression to mammary and ovarian cancer concurrently in the rat.  Tissue histology, 
degree of dysplasia, cellular proliferation status (Ki-67), hormone receptor levels 
(ER) and COX-2 expression were examined to validate this dual cancer model. 
 
Aim 2:  Determine the effect of tamoxifen on ovarian cancer using a rat model of 
simultaneous breast and ovarian cancer progression 
Tamoxifen is a proven prevention drug for ER+ mammary cancer, but its effect on 
ovarian cancer is not clear.  In this aim, we evaluated the possibility of tamoxifen as a 
dual-target prevention agent using the dual cancer model.  End point biomarkers 
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 including dysplasia score, Ki-67, ER, COX-2 and putative stem cell markers (Oct-4 
and ALDH-1) were examined. 
 
Aim 3:  Investigate the protective effect of tamoxifen against ovotoxic agents 
including DMBA and chemotherapy drugs 
In vivo and in vitro studies were conducted to study the effect of tamoxifen against 
ovarian follicle loss caused by DMBA and chemotherapy agents including 
cyclophosphamide and doxorubicin.  In vivo, female Sprague Dawley rats were 
treated with tamoxifen and DMBA or cyclophosphamide.  The effect of tamoxifen on 
rescuing ovarian follicles from DMBA or cyclophosphamide was examined by 
determining the number of follicles in the ovary.  In vitro, ovarian organ culture was 
performed to investigate local effects of tamoxifen on follicle numbers of DMBA-
treated ovaries.  Also, effects of tamoxifen on oocyte directly were examined by 
culturing in the presence of doxorubicin. 
 
The long term goals of this work are to 1) use the dual cancer model to screen for 
promising agents that decrease risks for both breast and ovarian cancer and 2) 
examine the mechanism by which tamoxifen inhibits toxicant-induced ovarian follicle 
loss. 
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 Abstract 
Women at increased risk for breast cancer are often also at increased risk for ovarian 
cancer, reflecting common risk factors and intertwined etiologies for both diseases.  
Unlike breast cancer prevention, primary ovarian cancer prevention has been 
impractical due to the low incidence, lack of risk and response biomarkers and 
difficulties in sampling ovarian tissue.  Challenges in the development of ovarian 
cancer prevention drugs, however, may be circumvented through the development of 
breast cancer prevention strategies that simultaneously decrease ovarian cancer.  In 
the present study, three commonly used mammary cancer carcinogen models [7,12-
dimethylbenz[α]anthracene (DMBA), N-methyl-N-nitrosourea (MNU) and estradiol 
(E2)] were combined with local ovarian DMBA administration to induce progression 
to mammary and ovarian cancer concurrently in the rat.  Animals were treated for 
three or six months and tissue histology as well as proliferation, hormonal and 
inflammation biomarkers were assessed.  Mammary and ovarian morphologies 
(measured as descriptive histology and dysplasia scores) were normal in vehicle 
controls. Mammary hyperplasia was observed in DMBA/DMBA (mammary 
carcinogen/ ovarian carcinogen) and MNU/DMBA -treated rats; however, ovarian 
preneoplastic changes were seldom observed after these treatments.  All E2/DMBA-
treated rats had mammary hyperplasia, atypia, ductal carcinoma in situ and/or 
invasive adenocarcinoma, while 50% also developed preneoplastic changes in the 
ovary (ovarian epithelial and stromal hyperplasia and inclusion cyst formation).  In 
both the mammary gland and ovary, decreased estrogen receptor alpha expression 
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 was detected and in the mammary gland elevated Ki-67 and cyclooxygenase-2 
expressions were observed.  This combined breast and ovarian cancer rat model 
(systemic E2 treatment and local ovarian DMBA) may be useful for future dual target 
breast and ovarian cancer prevention studies. 
 
Introduction 
Breast cancer chemoprevention trials are facilitated by minimally invasive techniques 
to sample breast tissue and the availability of a number of surrogate biomarkers to 
evaluate prevention drugs in phase II trials as well as the high incidence of this 
disease in phase III trials [28,29,139].  In contrast, sampling of ovarian tissue is 
invasive and appropriate biomarkers for ovarian cancer prevention trials are 
controversial [2].  Additionally, ovarian cancer is a relatively uncommon disease 
making testing of drugs for primary prevention difficult to justify.   One possible 
solution is to develop breast cancer chemoprevention drugs that simultaneously 
prevent ovarian cancer.  Indeed, successful human ovarian cancer chemoprevention 
has only been demonstrated incidentally during the course of breast cancer prevention 
trials (i.e. fenretinide) [47].  An initial obstacle to the development of dual target 
breast and ovarian cancer prevention drugs is the absence of an appropriate animal 
model.   
Rats are the most frequently used animal model for breast cancer 
chemoprevention, particularly chemical [7, 12-dimethylbenzanthracene (DMBA) and 
N-methyl-N-nitrosourea (MNU)] or hormonal [17β-estradiol (E2)] carcinogen models  
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 [60,62,140].  In intact females, these carcinogens induce a high incidence of 
mammary adenocarcinoma that express similar histology and biomarker expressions 
to the human disease within 2-5 months [60,62,140].  No commonly used preclinical 
model of ovarian cancer has been used to test prevention drugs but one promising 
method of inducing epithelial ovarian cancer is the direct application of DMBA to the 
ovarian surface epithelium.  This local ovarian DMBA treatment results in an 
approximate 30-40% occurrence of epithelial ovarian cancer (EOC) and a greater 
incidence of preneoplastic changes in the ovary [64-66].  In this study, these breast 
and ovarian cancer models were tested in combination in an effort to develop the first 
preclinical model of simultaneous breast and ovarian cancer progression.  
 
Materials and methods 
Animals and treatments 
Female Fischer 344 rats (Harlan Breeding Laboratories, Indianapolis, IN, n=6-8 per 
treatment*time group) weighing 50-55 g were housed three per cage in a climate- and 
light- (12L:12D) controlled environment, and received food and water ad libitum.  All 
experimental protocols were approved by the University of Kansas Medical Center 
Animal Care and Use Committee.  Within a week of arrival, rats were anesthetized 
using ketamine hydrochloride (80 mg/kg), atropine sulfate (0.2 mg/kg) and xylazine 
(8 mg/kg).  Hemiovariectomy was performed aseptically in order to concentrate 
ovulation upon the treated ovary and hasten a senescent hormonal milieu [141,142].  
In addition to increasing ovulation rate on the remaining ovary, Anzalone and 
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 colleagues have shown that hemiovariectomy mimics age-related alterations such as a 
lower incidence of regular cyclicity altered magnitude of the proestrus LH surge as 
well as reduced ovarian follicular reserve when compared to age-matched intact rats.  
The remaining ovary was treated by passing a DMBA-impregnated (2.5mm region 
dipped in melted DMBA) or vehicle 5-0 silk suture through the ovary twice such that 
the DMBA or vehicle region was apposed directly and gently secured to the ovarian 
surface epithelium.  Local ovarian DMBA application ultimately results in a 30-50% 
incidence of ovarian cancer arising from the surface epithelium within 12 months 
using this model [64-66].  Rats receiving ovarian DMBA were subsequently treated 
with mammary carcinogens: DMBA (10 mg/kg, p.o.), MNU (50 mg/kg, i.p.), or 17β-
estradiol (E2, 3.0 mg, pellet implant; Hormone Pellet Press, Leawood, KS). Rats 
(n=12) receiving vehicle-coated sutures were further treated with vehicle (corn oil; 
4ml/kg, p.o.; blank implants s.c.).   
 
Tissue Preparation 
Rats were sacrificed at 3 or 6 months post-treatment, serum collected and stored at -
80ºC.  Right thoracic mammary glands were excised, fixed in 4% paraformaldehyde 
(PFA) and embedded in paraffin.  Right abdominal-inguinal mammary glands were 
spread out onto a glass slide, fixed in 4% PFA and infused with alum carmine 
following a whole mount preparation protocol [143].  The ovary was bisected through 
the site of DMBA application.  One half was fixed in 4% PFA and embedded in 
paraffin while the remainder was snap frozen for future study.  
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 Immunohistochemistry 
Six-micron sections of mammary glands and ovaries were deparaffinized, rehydrated, 
and stained with hematoxylin & eosin (H&E).  H&E sections were evaluated for 
premalignant morphological changes associated with mammary adenocarcinoma 
(MAC) and epithelial ovarian cancer (EOC) progression [65,144] by an observer 
blinded to treatment groups.  Additional sections were prepared for immunostaining 
by antigen retrieval (99.9oC, 10mM citrate buffer, 20 minutes) and incubation with 
0.3% hydrogen peroxide (Lab Vision, Fremont, CA).  Non-immune serum or primary 
antibodies against estrogen receptor alpha (ER; 1;100; Clone SP1; rabbit monoclonal 
antibody; Lab Vision, Fremont, CA), cyclooxygenase-2 (COX-2; 1:50; RB-9072; 
rabbit polyclonal antibody; Lab Vision, Fremont, CA) and Ki-67 (1:25; Clone Ki-S5; 
mouse monoclonal antibody; Dako, Carpinteria, CA) were applied and visualized 
with DAB chromogen and biotinylated secondary antibodies.  All incubations were 
carried using a Dako LV-1 autostainer (Carpinteria, CA).  
 
Hormone assays 
Serum concentrations of E2 were determined by ELISA kit according to 
manufacturer’s protocol (DSL-10-4300, Diagnostic Systems Laboratories, Webster, 
TX).  All samples were run within the same assay and the intra-assay CV was <10%.  
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 Quantitative Analysis of Preneoplastic Lesions 
H&E sections of the mammary gland and ovary were evaluated for pre-neoplastic and 
neoplastic morphological changes associated with breast and epithelial ovarian cancer 
progression [65,144]. Mammary tissue was evaluated for preneoplastic changes 
including mild or severe ductal hyperplasia and hyperplasia with atypia as well as 
neoplastic changes such as ductal carcinoma in situ (DCIS) and invasive DC, 
corresponding to scores of 1-5, respectively. A score of 0 was given to animals with 
normal mammary histology.  Pre-neoplastic changes of the ovary were defined as 
surface (bursal flat) hyperplasia, inclusion cysts, stromal hyperplasia and papilloma.  
Scores of 0, 1 and 2 were given to each section according to the severity or the 
prevalence of each pre-neoplastic category (a score of 0 represent an absence of 
preneoplastic changes and a score of 2 indicates a high degree of abnormality).  
Sections from 3 different levels of the ovary from each animal were evaluated.  These 
preneoplastic criteria are the same as those used by Stewart and colleagues with this 
rat model of ovarian carcinogenesis [65]. 
Ki-67 and ER expression in the mammary ductal epithelia cells and ovarian 
surface epithelia and COX-2 expression in ovarian epithelia were quantified by 
counting immunoreactive epithelial cells and total epithelial cells (at least 1000 cells 
were evaluated per section).  The intensity of COX-2 immunostaining in the 
mammary gland was quantified with an automated cellular imaging system 
(ChromaVision, San Juan Capistrano, CA) [77]. Three random fields of each tissue 
section were selected for quantification (combined area evaluated = 1.56mm2), and 
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 the staining intensity was expressed as percent area occupied by COX-2-
immunoreactive cells. 
All continuous values are presented as the mean ± SEM and their statistical 
comparisons were made using two-way analysis of variance.  Differences were 
considered significant when P ≤ 0.05. 
 
Results 
Histopathology 
Mammary gland whole mounts:  In the mammary gland, DMBA, MNU and E2 
treatment increased ductal branching and area occupied by alveoli by 3 months and 
the impact of E2 was the most extensive among these three carcinogens.  These 
effects were further increased after 6 months of treatment (Figure 1B-D). Vehicle-
treated rats (3 and 6 month) showed normal mammary morphology (Figure 1A). 
Mammary histology:  Vehicle-treated (3 and 6 month) and systemic DMBA-treated 
(3 month) rats displayed normal histology showing scattered acini throughout the 
mammary gland each bearing a single layer of ductal epithelial cells surrounded by 
myoepithelial cells (Figure 1E).  Increased dysplasia scores were observed in 
carcinogen-treated animals (Table I).  Ductal hyperplasia was observed in some 
DMBA/DMBA- and MNU/DMBA -treated rats (3 and 6 month) and in all 3-month 
E2/DMBA-treated rats (Figure 1F and G).  Six months of systemic E2 induced ductal 
hyperplasia (2/6), ductal carcinoma in situ (DCIS, 3/6), and invasive adenocarcinoma 
(1/6) (Figure 1H). 
 38
 Ovarian histology: Local ovarian DMBA application caused increased ovarian 
dysplasia and both benign abnormalities such as local inflammation around suture 
materials, mild stromal hyperplasia and decreased follicle numbers (Figure 1J and K 
and Table I).  Combined systemic E2 and ovarian DMBA treatment further induced 
ovarian preneoplastic changes of epithelial origin in 50% rats (i.e. epithelial 
hyperplasia and inclusion cyst) following 6 month treatment (Figure 1L and Table I).  
Vehicle-treated rats showed normal ovarian histology with mild inflammation 
induced by suture materials (Figure 1I). 
 
Epithelial proliferation was stimulated by E2 treatment  
Ki-67 expression was localized in the nucleus of ductal epithelial cells in the 
mammary gland and surface epithelial cells in the ovary. Following 6 month 
treatment, Ki-67-immunoreactive cells were increased in E2/DMBA mammary glands 
when compared to controls and other carcinogen-treated rats (Figure 2A-C; P ≤ 0.05). 
Ovarian epithelial staining for Ki-67 increased significantly from 3 to 6 months in 
rats treated with E2/DMBA (P ≤ 0.05) but did not differ significantly from controls 
and other carcinogen-treated rats. 
 
Mammary COX-2 expression increased in E2/DMBA -treated rats 
COX-2 expression was elevated in the mammary gland of E2/DMBA-treated rats 
when compared to controls and other carcinogen-treated rats (3 month and 6 month) 
(Figure 2D-E; P ≤ 0.05).  Although COX-2 expression in the ovarian surface epithelia 
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 did not increase after carcinogen treatments, preneoplastic changes of epithelial origin 
in the ovary of E2/DMBA-treated rats showed strong immunoreactivity to COX-2 
(Figure 3).  
 
ER expression decreased with carcinogen treatment 
ER immunoreactivity in the mammary gland was decreased after 6 month systemic 
DMBA, MNU and E2 treatment (Figure 4A-C; P ≤ 0.05).  Ovarian DMBA similarly 
decreased the ER expression in the ovarian surface epithelium by 6 months of 
treatment when compared to controls (Figure 4D-F; P ≤ 0.05). 
 
Serum estradiol concentrations 
The sustained release E2 treatment provided a consistent and sustained increase in 
serum E2 when compared to DMBA-, MNU-, or vehicle- treatment (Table I; P ≤ 
0.05).  E2-related side effects including pituitary and uterine hyperplasia were 
observed in two animals.  Although ovarian granulosal proliferation was observed (in 
addition to epithelial and stromal ovarian hyperplasia) in all E2/DMBA treated rats, it 
was not considered a preneoplastic lesion for epithelial ovarian cancer when 
determining dysplasia scores. 
 
Discussion 
Breast and ovarian cancer have interdependent risk factors and women at increased 
risk for one of these cancers are often at risk for the other [145,146].  While active 
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 clinical trials are common for the evaluation of breast cancer prevention drugs, 
ovarian cancer prevention trials are seldom attempted due to low incidence of the 
disease, relatively invasive procedures for tissue sampling and the lack of well-
established serum or imaging-based biomarkers [2].  A logical approach to ovarian 
cancer chemoprevention may be the development of breast cancer prevention drugs 
that simultaneously decrease the risk of ovarian cancer.  Towards this end, the present 
study is intended to produce a preclinical model for the evaluation of simultaneous 
chemoprevention of breast and ovarian cancer. 
Systemic E2 and local ovarian DMBA induced preneoplastic changes in breast 
and ovary of the rat as demonstrated by elevated Ki-67 and COX-2 expression in 
addition to histological analysis.  Unlike systemic DMBA and MNU, systemic E2 
appeared to contribute not only to mammary carcinogenesis but also to the 
progression towards ovarian neoplasia.  This additive or synergistic effect of E2 
merits further exploration.  One possible explanation is that the proliferative effect of 
E2 may increase the mutation rate of ovarian surface epithelial cells [147] and 
therefore accelerate the incidence of ovarian preneoplastic changes.  Similarly, 
Stewart and colleagues reported that when combined with gonadotropin hormones, 
local ovarian DMBA induced more ovarian preneoplastic lesions compared to DMBA 
treatment alone [65]. 
In the present study, putative ovarian preneoplastic changes such as inclusion 
cysts, epithelial hyperplasia, papilloma, and stromal hyperplasia were used to 
evaluate progression towards ovarian cancer instead of actual cancer incidences.  
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 These criteria are the same as those of Stewart et al. in DMBA-induced ovarian 
adenocarcinoma of the rat [65].  While the presence of inclusion cysts in older 
women is common [148] and controversy concerning whether inclusion cysts are a 
preneoplastic lesion remains, many groups agree that ovarian inclusion cysts are a 
precursor for ovarian adenocarcinoma [149,150].  Studies have shown that the 
number of inclusion cysts is increased in ovaries from patients with ovarian 
carcinoma, contralateral epithelial ovarian tumors, or a family history of ovarian 
cancer compared to healthy subjects [151-154].   
Elevated COX-2 expression has been observed in several tumors including 
ovarian neoplastic lesion [49,50,73,81,155]; however, we found that overall ovarian 
epithelial COX-2 expression was not altered by E2/DMBA treatment while COX-2 
was highly expressed by ovarian inclusion cysts.  Recent studies have also revealed 
the relevance of COX-1 expression in ovarian tumors development [51,52,66] 
suggesting another target for ovarian chemoprevention and its role should be 
investigated using this combined breast and ovarian cancer model.   
Although this study was intended primarily to develop a practical model for 
the evaluation of dual target chemoprevention drugs against breast and ovarian 
cancer, our results also emphasize the interaction of the etiologies of ovarian and 
mammary cancer.  Previous studies showed that latencies of breast tumor formation 
induced by MNU, DMBA and E2 in the rat are approximately 3, 4 and 6 months, 
respectively [156-159]. However, systemic MNU and DMBA only caused 
precancerous mammary changes in the current experiment after 6 months of 
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 treatment.  This is likely due to hemiovariectomy since the removal of both ovaries 
completely abolishes the ability of mammary carcinogens to induce mammary tumors 
[160].  The intention of hemiovariectomy was to concentrate ovulation which is a risk 
factor for human ovarian cancer on the remaining treated ovary [161,162].  
Approximately 50% of E2/DMBA-treated rats developed preneoplastic changes in the 
ovary.  One way to further increase ovarian cancer progression might be to prolong 
the treatment (rats develop epithelial ovarian cancer from ovarian DMBA at 10-12 
months [66]), but this is difficult due to advanced mammary tumor formation by 6 
months of treatment.  Additionally, our intention was to parallel the approach of 
human cancer prevention trials which focus on reversible or preventable preneoplasia 
and associated biomarkers rather than actual cancer incidence [29,68]. 
In the present study, we have demonstrated that rats treated with systemic E2 
and local ovarian DMBA develop preneoplastic and neoplastic changes in the breast 
and ovary simultaneously.  This model benefits from apparent additive or synergistic 
effects of E2 and DMBA in early ovarian carcinogenesis unlike models addressing 
breast or ovarian cancer separately.  This approach is intended to facilitate the 
identification of promising cancer prevention drugs that simultaneously decrease 
progression to breast and ovarian cancer (e.g. postmenopausal SERMs or retinoids 
[47]) or reveal drugs that might incidentally decrease the incidence of one cancer 
while predisposing to the other (e.g. progesterone [45,46,163,164]).   While all 
women would potentially benefit from a well tolerated chemoprevention drug against 
breast and ovarian cancer, a more conservative estimate of benefit in the United 
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 States might be the approximately 10% of the female population considered at 
elevated risk for these diseases.   
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 Table I.  Mammary and ovarian dysplasia scores and serum E2 concentrations 
 
Statistical comparisons were made using two-way analysis of variance.  Dysplasia 
scores are present as mean ± SEM for each treatment group.  Histology sections of 
the mammary gland from each animal were given a score from 0-5, representing 
normal histology, mild/severe ductal hyperplasia, hyperplasia with atypia, ductal 
carcinoma in situ, and invasive carcinoma, respectively.  Ovarian pre-neoplastic 
changes include ovarian surface hyperplasia, inclusion cysts, stromal hyperplasia and 
papilloma.  Scores of 0, 1 and 2 was given to each section (3 sections per animal) 
according to the severity or the prevalence of each change.  Three scores from 
different levels of the ovary were summed to give a dysplasia score for each animal. 
 * differs significantly to controls (P < 0.05).   
** differs significantly to controls and * (P < 0.05).   
*** differs significantly to controls, * and ** (P < 0.05). 
 
Mammary Gland Ovaries E2 Serum Levels (pg/ml)  
Treatment 3.0  
Months 
6.0  
Months 
3.0  
Months 
6.0  
Months 
3.0  
Months 
6.0  
Months 
Vehicle 
Control 
0 0 0.8±0.5 0.8±0.1 60.98±5.98 50.2±8.1 
DMBA/ 
DMBA 
0 1.0±0.8* 3.6±0.7* 4.4±1.2* 42.66±1.53 45.0±5.2 
NMU/ 
DMBA 
0. 7±0.2* 0.8±0.2* 3.4±0.5* 4.0±0.8* 43.5±3.9 46.5±4.0 
E2/    
DMBA 
2.4±0.7** 3.5±0.5** 7.4±0.3** 9.5±0.9*** 133.6±21.8* 104.0±43.5* 
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Fig. 1.  Whole mounts (A-D) and mammary (E-H) and ovarian histology (I-L).  
DMBA/DMBA (ovarian/systemic)-treated rats (B, F and J) and MNU/DMBA-treated 
rats (C, G and K) showed increased ductal branching in whole mounts (B and C), 
increased alveoli in H&E sections (F and G), and absence of preneoplastic changes in 
the ovary (J and K).  All E2/DMBA-treated rats developed mammary preneoplastic or 
neoplastic changes (D and H) and 50% of them also showed ovarian preneoplastic 
changes (L; insert: magnified image of an inclusion cyst).  Scale bars = 1 mm (A-D), 
200 μm (E-L) and 50 μm (L insert).  Abbreviation: F = ovarian follicle, CL = corpus 
luteum, Su = suture material, HYP = epithelial hyperplasia, IC = inclusion cyst. 
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Fig. 2.  Mammary epithelial proliferation (Ki-67) was increased above controls at 6 
months in E2/DMBA-treated group (A and C) when compared to controls (B; P ≤ 
0.05).  Percentage COX-2 expression in mammary gland also increased in E2/DMBA-
treated groups (F) as compared to controls (E) and other carcinogen-treated groups 
following 3 month and 6 month treatment (D; P ≤ 0.05).  Arrows indicate positively 
stained mammary epithelial cells.  Scale bars = 100 μm.  For A and D, different 
letters indicates significant difference among different treatment groups. 
  
Fig. 3. Inclusion cysts found in the ovary of E2/DMBA-treatd ovary (adjacent section 
of Fig. 1L insert) showed positive COX-2 expression. Scale bar = 50 μm.  Non-
immune control not shown. 
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Fig. 4.  ER expression was downregulated in the mammary gland (A-C) and ovary 
(D-F) of carcinogen-treated rats when compared to controls after 6 month treatment 
(P ≤ 0.05). Arrows indicate positively stained mammary epithelial cells.  Scale bars = 
100 μm.  For A and D, different letters indicates significant difference among 
different treatment groups. 
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 Abstract 
Women at increased risk for breast cancer are at increased risk for ovarian cancer as 
well, reflecting common risk factors and intertwined etiology of the two diseases.  
We previously developed a rat model of elevated breast and ovarian cancer risk, 
allowing evaluation of dual target cancer prevention strategies.  Tamoxifen, a FDA-
approved breast cancer chemoprevention drug, has been shown to promote ovarian 
cysts in premenopausal women; however, the effect of tamoxifen on ovarian cancer 
risk is still controversial.  In the current experiment, Fischer 344 rats (n=8 per 
treatment group) received tamoxifen (TAM) or vehicle (CONT) in factorial 
combination with combined breast and ovarian carcinogen (17β-estradiol and 7, 12 
dimethylbenza[α]anthracene, respectively).  Mammary and ovarian morphologies 
were normal in CONT and TAM groups.  Carcinogen (CARC) treatment induced 
mammary dysplasia with elevated cell proliferation and reduced estrogen receptor 
alpha expression and promoted preneoplastic changes in the ovary.  In CARC+TAM-
treated group, tamoxifen reduced preneoplastic changes and proliferation rate in the 
mammary gland but not in the ovary compared to rats treated with carcinogen alone.  
Putative stem cell markers [Oct-4 and aldehyde dehydrogenase-1 (ALDH-1)] were 
also elevated in the mammary tissue by carcinogen and this expansion of the stem cell 
population was not reversed by tamoxifen.  Our study suggests that tamoxifen 
prevents early progression to mammary cancer but has no effect on ovarian cancer 
progression in this rat model. 
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 Introduction 
The development of promising breast cancer chemoprevention agents (i.e. selective 
estrogen receptor modulators (SERMs), aromatase inhibitors and retinoids 
[31,48,165]) has been permitted by minimally invasive techniques to access tissue, 
availability of surrogate biomarkers and relatively high incidence of the disease 
[25,166].  In contrast, ovarian cancer prevention trials are seldom attempted due to 
low disease incidence, the absence of accepted disease-specific biomarkers and the 
invasiveness of sampling for ovarian tissue.  Consequently, although most ovarian 
cancers are diagnosed at advanced stages resulting in high mortality rates, prevention 
of ovarian cancer remains elusive [2].  One practical approach for successful 
prevention of ovarian cancer may be the development of chemoprevention agents 
acting simultaneously against both ovarian and breast cancer.   
Breast and ovarian adenocarcinoma share numerous risk factors (e.g. estrogen 
exposure, ovulation, nulliparity, obesity, family history, BRCA1/2 mutations) and 
women at increased risk for one of these cancers are often also at risk for the other 
suggesting intertwined disease pathways [4,59].  Recent studies have shown that 
women receiving hormone replacement therapy are at increased risk for both cancers 
[167-169].  Alternatively, drugs that decrease ovarian cancer risk may actually 
increase the incidence of breast cancer (e.g. progesterone [38,170]).  To date, no 
human chemoprevention trials have been designed simultaneously targeting both 
breast and ovarian cancers despite the promise of such an approach.  Indeed, 
successful human ovarian cancer chemoprevention has only been demonstrated 
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 incidentally during the course of breast cancer prevention trials (i.e. fenretinide) [47].  
To investigate common chemoprevention strategies, our laboratory has developed a 
preclinical model that exhibits early changes of mammary and ovarian carcinogenesis 
in the rat [171].  This model allows observation of synergistic and antagonistic drug 
actions against breast and ovarian cancers that are ignored when each cancer is 
examined in isolation. 
Tamoxifen, the most commonly used breast cancer chemoprevention drug, 
blocks cell proliferation in the breast and has been shown to cause tumor regression 
and inhibit tumor formation, especially in ER+ breast tumors [104].  In the ovary, 
especially in premenopausal women, tamoxifen has been suggested to promote 
abnormal ovarian function and cyst formation, a putative ovarian preneoplastic 
change [32,105].  Tamoxifen and other SERMs have also been used to stimulate 
ovarian function in subfertile women with some question as to impact on ovarian 
cancer risk [172,173].   
Tamoxifen prevents 70% of ER+ breast cancers in high risk women, but fails 
to prevent ER- and some ER+ tumors [165].  One possibility for the lack of 
tamoxifen efficacy on 30% of ER+ cancers may be the presence of an E2-independent 
breast stem cell population [174].  The existence of self-renewing, pluripotent stem 
cells have been demonstrated both in human breast and rodent mammary glands 
[88,89].  Following recurrent carcinogen exposure, these long-lived breast stem cells 
are thought to accumulate mutations leading to tumor formation.  The size of the 
breast stem cell pool has therefore been hypothesized to serve as a determinant of the 
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 likelihood for breast cancer incidence.  Indeed, several studies have suggested a 
strong correlation between increased number of breast stem cells and elevated breast 
cancer risk as well as a possible intervention that targets stem cell for cancer 
treatment and prevention [175-178].  In the current study, we use a combined breast 
and ovarian cancer model to examine the effect of tamoxifen on markers of cancer 
risk, stemness and progression in the ovary and mammary gland during 
carcinogenesis. 
 
Materials and methods 
Animals and treatments 
Female Fischer 344 rats (Harlan, Indianapolis, IN, n = 8 per treatment group) 
weighing 50-55 g were housed in a climate and light (12L:12D) controlled 
environment and received food and water ad libitum.  All experimental protocols 
were approved by the University of Kansas Medical Center Animal Care and Use 
Committee.  Animals were randomly assigned into 4 different treatment groups as 
shown in Table 1.  Rats were anesthetized using ketamine hydrochloride and xylazine 
(80 and 8 mg/kg, respectively).  Hemiovariectomy was performed aseptically to 
concentrate ovulation upon the remaining ovary and hasten a senescent hormonal 
milieu [141,142] as these are risk factors of human ovarian cancer [171,179,180].  
The remaining ovary was treated by passing a 7, 12 dimethylbenza[α]anthracene 
(DMBA)-impregnated (2.5 mm region dipped in melted DMBA) or vehicle 5-0 silk 
suture through the ovary twice such that the DMBA or vehicle region was apposed 
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 directly and gently secured to the ovarian surface epithelium.  Rats receiving ovarian 
DMBA were subsequently treated with 17β-estradiol (E2, 1.5mg, pellet implant, 
Hormone Pellet Press, Leawood, KS) [62].  Our laboratory has previously shown that 
this treatment combination promotes progression to simultaneous mammary and 
ovarian cancer in the rat following 6 months of treatment [171].  Rats were further 
treated with tamoxifen (5 mg, pellet implant, Hormone Pellet Press) or vehicle to test 
the effect of tamoxifen in early mammary and ovarian cancer [157].   
 
Tissue preparation 
Rats were killed by decapitation at 6 months post-treatment and the right thoracic 
mammary glands were fixed in 4% paraformaldehyde (PFA) and embedded in 
paraffin.  Right abdominal mammary glands were spread onto a glass slide, fixed in 
4% PFA overnight, hydrated, infused with alum carmine (4 days), dehydrated, 
cleared in xylene, and stored in methyl salicylate.  Left thoracic mammary glands 
were snap frozen and stored at -80°C.  The ovary was bisected through the site of 
DMBA application.  One half was fixed in 4% PFA and embedded in paraffin while 
the remainder was snap frozen and stored at -80°C.  
 
Immunohistochemistry 
Six-micron sections of mammary glands and ovaries were deparaffinized, rehydrated, 
and stained with hematoxylin and eosin.  Mammary and ovarian sections 
(midsaggital, at 3 different equidistant levels per tissue) were evaluated for 
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 morphological changes associated with early progression to mammary 
adenocarcinoma (MAC) and epithelial ovarian cancer (EOC) by an observer blinded 
to treatment group identity [65,144].  Adjacent sections were prepared for 
immunostaining by antigen retrieval (93oC, 10mM citrate buffer, 25 minutes) and 
incubation with 0.3% hydrogen peroxide (Lab Vision, Fremont, CA).  Non-immune 
serum or primary antibodies against Ki-67 (1:100; Clone Ki-S5; rabbit monoclonal 
antibody, Lab Vision), estrogen receptor alpha (ERα; 1:200; MC-20; mouse 
monoclonal antibody, Santa Cruz), ALDH1A1 (1:150; rabbit polyclonal; Abcam, 
Cambridge, MA) or Oct-3/4 (1:50, mouse monoclonal, Santa Cruz) were applied and 
visualized with biotinylated secondary antibodies (Lab Vision) and diaminobenzidine 
(DAB) chromogen.  All incubations were carried out using a Dako LV-1 autostainer 
(Carpinteria, CA).  
 
Protein isolation and immunoblotting 
Samples of mammary gland (n = 4) and ovary (n = 4) from all treatment groups were 
homogenized in lysis buffer (Cell Signaling Technology, Danvers, MA) with 1 mM 
phenylmethylsulfonyl fluoride.  The lysates were centrifuged at 10,000g for 15 
minutes at 4°C and supernatant collected.  Protein concentrations were measured 
using a BCA protein assay kit (Pierce, Rockford, IL).  Following boiling for 5 
minutes in Laemmli sample buffer (Bio-Rad, Hercules, CA), samples (25µg protein) 
and ladders (Kaleidoscope prestained standards, Bio-Rad) were run on 10% Tris-HCl 
Criterion Precast gels (Bio-Rad) under reducing conditions and transferred onto 
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 nitrocellulose membrane.  Membranes were blocked with 10% milk in Tris-Buffer 
Saline with Tween-20 (TBST) for 1 hour at room temperature and incubated with 
antibodies against ALDH1A1 (1µg/ml), cyclooxygenase-2 (COX-2; 2µg/ml, rabbit 
polyclonal, LabVision), or Oct-3/4 (1:200) at 4°C overnight.  Following washing in 
TBST, blots were incubated in peroxidase-conjugated donkey anti-mouse, anti-rabbit 
or anti-goat antibodies (Jackson ImmunoResearch, West Grove, PA) for 2 hours at 
room temperature and washed.  Heart tissue lysates were used as positive control 
[181] and primary antibody omission was used as negative control.  Protein signals 
were visualized using chemiluminescent substrate (Pierce) and protein bands were 
quantified using GelPro.  Equal protein loading was confirmed by stripping 
(BlotFresh, SignaGen, Gaithersburg, MD) and reprobing the membranes with β-actin 
antibody (1:20,000, goat polyclonal, sc-1616, Santa Cruz).  Data are presented as 
integrated optical densities. 
 
Quantitative Analysis of Preneoplastic Lesions 
Mammary sections stained with H&E were evaluated and each section was assigned a 
dysplasia score according to the presence of pre-neoplastic and neoplastic lesions 
associated with breast cancer progression [144,171].  A score of 0 represented normal 
mammary histology.  Preneoplastic changes included mild (score = 1) or severe (2) 
ductal hyperplasia and/or hyperplasia with atypia (3).  Neoplastic changes included 
ductal carcinoma in situ (DCIS, score = 4) and invasive cancer (5).  The sum of 
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 scores from all 3 sections from each animal was used as the total dysplasia score; a 
value ranging from 0 to 15.   
 Pre-neoplastic changes of the ovary were defined as surface hyperplasia, 
inclusion cysts, stromal hyperplasia and papilloma, each being a separate histologic 
parameter [65,66,171].  For each ovarian section, each parameter was given a score of 
0, 1, or 2, based on the severity or prevalence of each pre-neoplastic category (i.e. a 
score of 0 represented normal histology, a score of 1 corresponded to a moderate 
prevalence or degree of change and a score of 2 indicated a high incidence or degree 
of abnormality).  Scores for all 4 histologic parameters were added up to give a 
dysplasia score for each ovarian section.  The sum of all 3 dysplasia scores for each 
animal gave rise to the total dysplasia score, a value ranging from 0 to 24.  These 
preneoplastic criteria are the same as those used by Stewart et al. with this rat model 
of ovarian adenocarcinoma [65]. 
Ki-67, and ERα expression in the mammary ductal epithelia cells and ovarian 
surface epithelium was quantified by counting immunoreactive cells and total cells (at 
least 1000 cells were evaluated per section) and presented as % immunoreactive 
epithelial cells.  Location and distribution of ALDH-1 and Oct-3/4 expression were 
documented.  All data are presented as the mean ± SEM.  Protein levels of Ki-67, 
ERα, COX-2, ALDH-1 and Oct-3/4 expression determined by immunohistochemistry 
and western blot were analyzed using one-way analysis of variance with treatment 
type as main effect.  Dysplasia scores were analyzed using a nonparametric test 
(Mann Whitney test).  Differences were considered significant when p≤0.05.   
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 Results 
Tamoxifen blocks mammary carcinogenesis 
Mammary gland whole mounts.  Control and TAM rats had normal mammary 
morphology (Figure 1a, b).  Carcinogen (E2+DMBA) treatment increased area 
occupied by alveoli (Figure 1c).  This effect was markedly reduced by tamoxifen in 
CARC+TAM group (Figure 1d).   
Mammary tissue histology.  Controls showed a normal appearance of lobular/acinar 
units surrounded by abundant adipose tissue (Figure 1e).  These units constituted a 
single layer of myoepithelium and inner mammary epithelial cells.  TAM animals 
also showed normal mammary histology (Table 2; Figure 1f).  All CARC animals 
exhibited pathologic mammary histology ranging from hyperplasia to disseminated 
DCIS and had higher dysplasia scores when compared to controls (Figure 1g; Table 
2, p< 0.0001).  In CARC+TAM rats, the number and morphology of lobular units 
were restored to near normality (Figure 1h).  These rats also showed mildly increased 
ductal branching and enlarged intraductal lumen as compared to controls but no 
dysplastic foci were present in any of these animals (Table 2). 
 
Tamoxifen neither blocks nor accelerates the progression to ovarian cancer in a rat 
model 
Controls showed normal ovarian morphology with mild inflammatory reaction to 
suture materials and rare inclusion cysts (Figure 2a, e; Table 2).  Compared to 
controls, TAM rats showed a slight increase in dysplasia score mostly due to the 
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 occasional presence of inclusion cysts; however, this difference was not significant 
(p= 0.20, Figure 2b, f; Table 2).  Consistent with our previous findings, CARC rats 
received higher dysplasia score when compared to controls (p< 0.0001) and showed 
markedly abnormal ovarian morphology with disorganized granulosal clusters, 
stromal hyperplasia, epithelial hyperplasia, papilloma and glandular cystic changes 
resembling inclusion cysts (Figure 2c, g; Table 2).  In CARC+TAM group, tamoxifen 
did not reduce the degree of ovarian preneoplasia following carcinogen treatment (p= 
0.09; Figure 2d, h; Table 2).  Interestingly, tamoxifen treatment seemed to increase 
the number of ovarian follicles when compared to those of the CARC group (data not 
shown). 
 
Expression of Ki-67, ERα and COX-2 in mammary gland and ovary under normal 
or dysplastic conditions  
Ki-67 expression was localized in the nucleus of ductal epithelial cells in the 
mammary gland.  Average numbers of Ki-67 positive cells per 100 ductal epithelia 
were 5.17 ± 2.11, 4.58 ± 1.93, 22.94 ± 3.57, and 8.75 ± 0.79 in CONT, TAM, CARC, 
and CARC+TAM animals, respectively.  These data showed that cellular proliferation 
was elevated in the mammary gland of CARC-treated animals when compared to 
CONT (p < 0.0001) and TAM (p < 0.0001) animals.  Tamoxifen inhibited 
carcinogen-induced Ki-67 elevation in CARC+TAM rats when compared to CARC 
rats (p = 0.0003; Figure 3).  Very few ovarian surface epithelial cells expressed Ki-67 
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 (less then 0.2% immunoreactivity) and there was no difference in expression among 
different treatment groups (p > 0.05). 
ERα expression.  Carcinogen treatment depleted ERα expression (immunoreactivity = 
0.25 ± 0.06%; Figure 3) in the mammary gland when compared to control (10.30 ± 
1.86%, p < 0.0001) and TAM-treated animals (11.87 ± 0.88%, p < 0.0001).  While no 
significant differences were detected, there was a trend for ERα expression to 
increase in response to TAM treatment in CARC+TAM animals (3.61 ± 0.25%, p = 
0.063) when compared to CARC group.  In the ovary, percentages of ERα 
immunoreactivity in ovarian surface epithelium were 40.97 ± 5.00, 47.45 ± 1.57, 
41.69 ± 5.98 and 40.68 ± 6.66 for CONT, TAM, CARC, and CARC+TAM animals, 
respectively.  No change in ERα expression was found in the ovary among different 
treatment groups. 
Inflammation biomarker.  COX-2 protein level was elevated in the mammary gland 
of CARC rats (IOD = 517.49 ± 197.27) when compared to CONT (11.47 ± 0.56, p = 
0.0067) and TAM (37.61 ± 8.28, p = 0.0089) animals.  Tamoxifen treatment reduced 
COX expression in CARC+TAM rats when compared to CARC group (7.60 ± 1.00, p 
= 0.0065; Figure 4A and 4B).  In the ovary, COX-2 expression was not altered by 
CARC treatment (p > 0.05).   
 
Levels of putative stem cell markers in the mammary gland and ovary 
In the mammary gland, immunoblot analysis showed that Oct-3/4 and ALDH-1 
expression were increased in CARC rats compared to controls (Figure 4A and B, p = 
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 0.014 and 0.012, respectively).  Surprisingly, while TAM drastically reduced 
histological progression to breast cancer, TAM had no effect on the induction of stem 
cell markers by sustained exposure to estrogen.  Our results showed that ALDH-1 and 
Oct-3/4 levels between CARC and CARC+TAM animals and between CONT and 
TAM animals do not differ (p > 0.05, Figure 4).  Immunohistochemistry revealed that 
while no immunoreactivity was observed in ductal epithelial cells of CONT and TAM 
animals, ALDH-1-positive cells were present in the cytoplasm of a few lobules in 
CARC and CARC+TAM animals (Figure 4C).  However, immunoreactivity of Oct-
3/4 was not observed in the selected mammary gland sections.  While the stem cell 
hypothesis has been explored in breast carcinogenesis, no putative stem cell markers 
have been suggested to be associated with ovarian carcinogenesis.  In the current 
study, immunohistochemistry data suggest that ALDH-1 and Oct-3/4 are not 
expressed in ovarian surface epithelia. 
 
Discussion 
Mammary gland 
Tamoxifen inhibited mammary cancer progression in our preclinical model of 
breast and ovarian carcinogenesis, consistent with previous data from clinical trials 
and animal studies [165,182].  Ki-67, a proliferation marker, and COX-2, an 
inflammation marker, are potential markers of breast cancer risk and have been used 
as surrogate markers of response in human phase II chemoprevention trials [68].  In 
our rat model, Ki-67 and COX-2 also correlated with progression of mammary 
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 carcinoma.  Mammary ERα expression is down-regulated in CARC animals 
consistent with previous studies showing the loss of ERα following E2-initiated cell 
proliferation [171,183]; however, it is also possible that the loss of ERα is temporary 
and is caused by ligand-induced receptor degradation [184].     
 
Ovary  
The current study is the most detailed experiment investigating the effect of 
tamoxifen on ovarian physiology and cancer progression.  While our study showed 
that tamoxifen does not retard ovarian cancer, this negative finding is very important 
and in agreement with the human literature while providing more intensive biomarker 
and histopathology data than in human study.  Although there seemed to be a slight 
increase in dysplasia in the ovary of animals treated with tamoxifen alone when 
compared to controls, this elevation was not significant.  While there is a possibility 
of cancer incidence with longer tamoxifen administration, six months treatment (one 
quarter of life-span in rats) in the current experiment far exceeds the recommended 
treatment time for women taking tamoxifen (less or equal to 5 years).   
Women taking tamoxifen have an increased risk for developing follicular 
cysts in the ovary [32,105], and it has been suggested that tamoxifen-induced ovarian 
cysts may contribute to increased risk of ovarian cancer [185].  However, in the 
current experiment, tamoxifen neither augments nor diminishes preneoplastic lesions 
induced by carcinogen treatment in the ovary in our high risk model.  Our results 
therefore suggest that tamoxifen, as a common prevention therapy for breast cancer, 
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 does not affect ovarian cancer risk in animals at high risk for both mammary and 
ovarian cancer.  In, addition COX-2 levels remained unchanged among difference 
treatment groups in the current experiment.  Recent studies revealed the relevance of 
COX-1 but not COX-2 expression in ovarian tumors development [51].  The role of 
COX-1 in mammary and ovarian carcinogenesis should be further investigated using 
this model.   
 
Stem cell biomarkers  
Oct-4 is a transcriptional factor expressed by early embryonic and germ cells 
and has been used to identify pluripotent cell populations [101].  ALDH-1, an enzyme 
that is required for the conversion of retinol to retinoic acids, is highly enriched in 
hematopoietic stem cells and researchers have suggested its presence in breast stem 
cells as well [102].  Our data showed increased expression of both markers in the 
mammary gland of rats treated with carcinogens.  This finding suggests that stem cell 
populations are expanded during mammary carcinogenesis in our model.   
Estrogen is used to induce mammary carcinogenesis in the current 
experiment.  The mechanism by which estrogen acts on stem cell number is still 
unclear since most studies agree that breast stem cells are ER- [177].  However, 
studies have also shown that dysregulation of breast stem cells, or an increased stem 
cell pool size, can be induced by exposure to elevated breast epithelial mitogens such 
as insulin-related growth factor-1 and steroid hormones including estrogens 
[186,187].  One rationale for this effect of estrogen is an indirect mechanism or stem 
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 cell niche; thus, estrogen acts on ER+ cells surrounding the stem cell and promotes 
paracrine signaling [177,188].  Interestingly, rats treated with carcinogen + tamoxifen 
were rescued from progression towards mammary cancer but still exhibited elevated 
mammary stem cell markers.  This observation may suggest that tamoxifen, while 
retarding breast cancer progression, does not act upon the stem cell population but 
rather has its effects on the differentiated epithelia.  This in turn is consistent with the 
absence of ER in the breast stem cell [177]; however, our understanding of mammary 
stem cell markers and biology will need to improve to fully answer this question.  
 
Combined model of breast and ovarian cancer prevention 
The rat model of breast and ovarian carcinogenesis used here, while allowing 
us to observe synergistic and antagonistic drug action in our search for a dual target 
prevention strategy, has some inherent limitations.  The human population best 
modeled by these experiments is probably menopausal women on hormone 
replacement therapy and the results may be less relevant to other populations. This 
model is also focused on early changes of breast and ovarian cancer, since these are 
the intended targets for cancer chemoprevention, rather than following animals to 
tumor incidence.  While this shortens the trials and parallels our human 
chemoprevention studies [68,189], it does entail the use of surrogate endpoint 
biomarkers for cancer with their inherent uncertainties.  
Breast and ovarian cancer share similar etiology (endocrine background, risk 
factors, epithelial origin, etc) reflecting common disease pathways; however, these 
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 cancers show discrepancy in terms of development and cancer cell type.  This 
difference in pathology may be due to differences in the cells of origin or the 
hormonal milieu surrounding them.  Despite these differences in the later stages of 
disease, the initiation factors for breast and ovarian cancer are similar and therefore, it 
is plausible to target both cancers simultaneously for prevention. 
In the present study, we have demonstrated that, while tamoxifen is an 
effective breast cancer prevention drug for ER+ disease, it does not retard the 
development of ovarian preneoplasia and therefore is not ideal for simultaneous 
prevention of breast and ovarian cancer.  Our results also suggest that while 
tamoxifen has been shown to induce ovarian cyst formation, it does not increase 
ovarian cancer risk in this model.  Mechanistically, hormonal mammary 
carcinogenesis in this model is accompanied with elevated expression of ALDH-1 
and Oct-4 and this putative expansion of the ALDH-1- or Oct-4-positive stem cell 
population is not reversed by tamoxifen cancer chemoprevention.  These data also 
confirm that our combined breast and ovarian cancer model allows the observation of 
synergistic and antagonistic drug action on the breast and ovary.  Simultaneous breast 
and ovarian cancer prevention is biologically feasible and may offer the best 
possibility for ovarian cancer prevention.  Future studies will include investigation of 
common disease pathways and evaluation of other candidate drugs for simultaneous 
chemoprevention of both breast and ovarian cancers using this model. 
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Table 1:  Experimental groups to examine the effect of tamoxifen on the progression 
towards concurrent mammary and ovarian cancer.  CONT = vehicle-treated animals, 
TAM = tamoxifen-treated animals, and CARC = carcinogen-treated animals. 
Treatment Group  CONT TAM CARC CARC+TAM
Ovarian treatment Vehicle Vehicle DMBA DMBA 
Systemic treatment Vehicle Vehicle E2 E2
Tamoxifen treatment Vehicle Tamoxifen Vehicle Tamoxifen 
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 Table 2.  Mammary and ovarian dysplasia scores. 
Animal group Mammary Gland Ovaries 
CONT 0 0.44±0.24 
TAM 0 1.38±0.32 
CARC 7.88±0.79* 7.29±1.09* 
CARC+TAM 0 5.83±0.54* 
 
Dysplasia scores are present as mean ± SEM for each treatment group.  CONT = 
control, TAM = tamoxifen-treated animals, and CARC = carcinogen-treated animals.  
* differs significantly from control (p < 0.05).  In the ovary, the differences between 
CONT and TAM as well as CARC and CARC+TAM were not significant (p = 0.20 
and 0.085, respectively). 
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Figure 1: Whole mounts (a-d, 20x), and H&E sections (e-h, 100x) of the mammary 
gland.  Controls (CONT) and tamoxifen-treated (TAM) animals showed normal 
mammary histology (a-b, e-f).  Carcinogen treatment (CARC) caused preneoplasia 
and neoplasia (c and g) and this effect was blocked by CARC+TAM (d and h).  
Secreting mammary glands were observed in CARC+TAM rats.  Scale bars = 5 mm 
(a-d), 200 μm (e-h). 
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Figure 2: H&E sections of the ovary.  Scale bars = 600 μm (a-d), 50 μm (e-h and 
insert).  CONT = controls, TAM = tamoxifen-treated rats, CARC = E2/DMBA-treated 
rats, OSE = ovarian surface epithelia, Pa = papilloma, IC = inclusion cyst. 
 
 70
  
Figure 3: Ki-67 and ER alpha immunostaining in the mammary gland.  Mammary 
epithelial proliferation (% Ki-67) was increased above controls in CARC animals (a 
and c, p<0.05).  CARC+TAM treatment reduced this elevation (c and d, p<0.05).  
TAM alone did not effect % Ki-67 compared to controls (a and b).  Carcinogen 
treatment depleted ER expression in the mammary gland when compared to control 
and TAM-treated animals (e-g, p<0.05).  There was a trend for ERα expression to 
increase in response to TAM treatment in CARC+TAM animals when compared to 
CARC group; however, this difference was not significant (g and h, p= 0.063). Scale 
bars = 100 μm (a-d), 50 μm (e-h).  
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 Figure 4: Cyclooxygenase 2 (COX-2), Oct-4, and aldehyde dehydrogenase 1 
(ALDH-1) expression in the mammary gland.  A. Representative western blots of 
mammary glands from rats treated with vehicle (C1, C2), tamoxifen (T1, T2), 
carcinogen (CA1, CA2), and carcinogen + tamoxifen (CA+T1, CA+T2).  β-actin was 
used as a loading control.  B. Quantitative analysis of western blots showing that 
COX-2, Oct-4 and ALDH-1 levels (y axis represents IOD, Integrated Optical 
Density) were elevated following carcinogen treatment (CARC) compared to controls 
(CONT).  COX-2 expression was reduced by tamoxifen (TAM) in CARC+TAM 
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 group.  Letters indicate significant differences among different treatment groups.  C. 
Cytoplasmic ALDH-1 immunostaining was observed in a few luminal epithelial cells 
in the mammary gland of CARC animals (Arrow).  No immunoreactivity was 
observed in CONT and TAM animals.  Scale bars = 50 μm. 
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Chapter IV 
 
 
 
Tamoxifen as a molecular shield to protect the ovary against DMBA 
and cyclophosphamide-induced follicle loss in the rat 
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 Abstract 
Infertility and premature ovarian failure are common side effects of cytotoxic 
chemotherapy.  Embryo freezing is the only established option to preserve fertility 
and it has significant limitations in efficacy.  Our laboratory has serendipitously 
discovered a protective effect of tamoxifen, a selective estrogen receptor modulator, 
against the destruction of oocytes by toxic chemicals.  The current study is designed 
to explore this novel ovoprotective property of tamoxifen.  In vivo, 5-week-old female 
rats received placebo or tamoxifen pellets (5mg) followed by weekly injections of 
vehicle, 7,12-dimethylbenzanthracene (DMBA) or cyclophosphamide (Cy, the most 
ovotoxic chemotherapy), and total numbers of follicles in the ovary were determined.  
In vitro, ovaries from 4 day old pups and mature oocytes were exposed to DMBA and 
doxorubicin, respectively, with or without 4-hydroxytamoxifen (4HT) to examine 
local effects of tamoxifen on DMBA-induced follicle loss and doxorubicin-induced 
oocyte fragmentation.  Follicle populations were classified and counted in every 10th 
sections of the ovary.  Results confirmed that numbers of primordial and total 
follicles were reduced by DMBA and Cy (p<0.05) and this reduction was prevented 
by tamoxifen in vivo and 4HT in vitro.  In oocyte culture, doxorubicin elevated the 
percentage of fragmented oocytes, an effect that was antagonized by 4HT.  In 
summary, this study demonstrated a protective effect of tamoxifen against DMBA, a 
well characterized ovotoxicant, Cy, the most ovotoxic cancer drug and another 
chemotherapy agent, doxorubicin.  Tamoxifen may therefore provide a novel 
protection to the ovary against chemotherapy-induced infertility in premenopausal 
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 cancer patients.  Tamoxifen has already been tested for safe first-line use for several 
cancers allowing these observations to be readily translated from bench to bedside. 
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 Introduction 
With over 2 million oocytes at birth, a woman ovulates only 300-500 eggs during her 
reproductive life span while the remaining majority becomes atretic [190].  Standard 
cytotoxic cancer therapy can destroy ovarian follicles and often leads to infertility or 
premature ovarian failure, permanently affecting quality of life for young women 
with cancer [111,191].  Previously this infertility and iatrogenic menopause was 
viewed by physicians and patients as an acceptable cost of curative chemotherapy and 
radiation regimens.  However, as more women survive their cancers and strive to 
resume normal family life, sterilization and premature menopause from cancer 
therapy has become a major survivorship issue [192].  With earlier diagnoses and 
higher survival rates, the problem of infertility in cancer patients will only increase.  
To date, there is no established treatment capable of protecting the ovary from the 
toxic effects of chemotherapy. 
The only approved fertility preservation method for female cancer patients is 
assisted reproduction followed by embryo cryopreservation for future transfer; 
however, this procedure causes a delay in chemotherapy by several weeks to months, 
is expensive and invasive, requires current partners or sperms and has low success 
rate [193].  Experimental methods such as oocyte freezing also delay cancer treatment 
and has little success to date due to fragility of the oocytic meiotic spindle and 
formation of ice crystals during freezing [117].  Ovarian tissue cryopreservation is 
also available experimentally but it is surgically invasive, has a risk of possible cancer 
cell transmission, and causes ischemic damage to the ovary leading to poor oocyte 
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 viability [120].  One experimental therapy that appears to protect gonadal function is 
hypothalamic suppression with GnRH agonists [122,194].  Blumenfeld and 
colleagues have documented chemoprotective effects of GnRH suppression against 
infertility in women following chemotherapy for lupus and lymphoma [121,124,195].  
However, treatment with GnRH agonists does not appear to protect from radiation-
induced ovotoxicity [126] and other studies have not observed consistent outcome 
from this protocol [125].  Fertility preservation options that provide protection of the 
ovary for young female cancer patients are urgently needed. 
Our laboratory serendipitously observed a protective effect of the commonly 
used anticancer drug tamoxifen (TAM) against ovarian follicular loss caused by 7,12-
dimethylbenzanthracene (DMBA) in a preclinical cancer prevention study [196].  
TAM is a selective estrogen receptor modulator (SERM) and the most commonly 
used drug for treatment and prevention of hormonal-responsive breast cancer [197].  
The estrogenic or anti-estrogenic effects of TAM are determined in large part by the 
complement of ER isoforms, estrogen response element polymorphisms, corepressor 
and coactivator plentitudes, and existing concentrations of endogenous estrogens 
[198].  While chronic (5 years) use of tamoxifen is associated with an increased risk 
of endometrial cancer [165], short term use of tamoxifen has been tested extensively 
and proven to be safe as first line combination therapy for lymphoma due to its 
potential alleviation of multidrug resistance [199-201].   
Two of the most extensively studied ovotoxic agents are DMBA and 
cyclophosphamide (Cy).  DMBA, a polycyclic aromatic hydrocarbon, is commonly 
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 used in rodent models to induce a variety of cancers [64,127].  In addition to being a 
carcinogen, DMBA also destroys follicular reserve and causes ovarian failure 
[128,129].  While the mechanism by which DMBA targets and destroys follicles in 
the ovary is not entirely understood, many investigators have suggested that apoptosis 
plays a critical role [129,130].  Cy, also known as Cytoxan, is commonly used as a 
part of standard regimen therapy of many malignancies including lymphomas, 
leukemia, and solid tumors.  Cy is a nitrogen mustard alkylating agent which forms 
adducts with DNA and is considered to be the most ovotoxic cancer drug resulting in 
a high rate of ovarian failure in cancer patients [110,134]. Doxorubicin (DOX), also 
known as Adriamycin, intercalates with DNA and inhibits helicases and 
topoisomerases and is another frequently studied chemotherapeutic agent known for 
its ovotoxicity. Similar to DMBA-induced ovarian toxicity, Cy and DOX has been 
shown to target the ovary directly and cause atresia [138].  However, while some 
studies have shown that DMBA and DOX deplete ovarian follicles by elevating Bax 
protein and apoptosis in oocytes [129]; others have suggested Cy-induced follicle 
depletion is driven by apoptosis in oocyte supporting cells or granulosa cells [138].   
In the current study, we test a novel use of tamoxifen to protect the ovary and 
rescue ovarian reserve from DMBA, Cy and DOX-induced gonadal toxicities in 
female Sprague Dawley rats.  Results from this study may lead to improved fertility 
preservation and quality of life, especially following cancers with high incidence for 
young females. 
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 Materials and methods 
Animals and treatments 
Pregnant and 4-6 week old virgin female Sprague Dawley rats (Harlan Breeding 
Laboratories, Indianapolis, IN) were housed in a climate and light (12L:12D) 
controlled environment and received food and water ad libitum.  All experimental 
protocols are approved by the University of Kansas Medical Center Animal Care and 
Use Committee.  
 
DMBA experiment:  One week after arrival, rats (n = 6 per treatment group) were 
randomly assigned into the following groups:1) controls, 2) 5mg TAM [196], 3) 5mg 
DMBA, 4) 10mg DMBA [202], 5) 5mg DMBA+TAM, 6) 10mg DMBA+TAM.  Rats 
were anesthetized with ketamine hydrochloride and xylazine (80 and 8 mg/kg, 
respectively) and pellets containing 5mg TAM or matching placebos (Hormone Pellet 
Press, Leawood, KS) were implanted subcutaneously between the scapulae on day 0.  
Each animal also received 2 injections of DMBA (5 or 10mg dissolved in 0.5ml corn 
oil per dose, Sigma St. Louis, MO) or vehicle on day 0 and 7 [202]. 
 
Cy experiment:  Rats (n = 6 per treatment group) were randomly assigned into 4 
treatment groups: 1) controls, 2) 5mg TAM, 3) 35mg/kg Cy [203], 4) 50mg/kg Cy, 5) 
35mg/kg Cy + TAM, 6) 50mg/kg Cy + TAM.  Rats were anesthetized as described 
above and implanted with pellets containing 5mg TAM or matching placebos (60 day 
release; Innovative Research of America, Sarasota, Florida) on day 0.  On day 2 and 
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 weekly thereafter, rats received Cy (35 or 50mg/kg in 0.9% NaCl, i.p.; Sigma) or 
vehicle injections for 4 weeks [136].     
 
Tissue preparation   
One week following the last DMBA treatment or three days following the last Cy 
injection, rats were sacrificed by decapitation and serum was collected and stored at -
80°C.  The left ovary was excised, weighed, fixed in 4% paraformaldehyde (PFA; 
Electron Microscopy Sciences, Hatfield, PA) and embedded in paraffin and right 
ovary was snap-frozen and stored at -80°C. 
 
Ovarian organ culture 
Postnatal day 4 female pups were killed by decapitation [204].  Ovaries (n= 6 per 
treatment) were removed, oviduct and excess tissue trimmed and placed on a piece of 
Millicell-CM membrane which was pre-incubated and floating on 250µl of 
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (D-MEM/ F12, 1:1) 
containing 0.1% bovine serum albumin (BSA), 50 µg/ml ascorbic acid, 2.75 µg/ml 
transferrin, 1mg/ml Albumax, and 50 I.U./ml penicillin/ 50 µg/ml streptomycin in a 
24-well plate [205] with the following treatments;  1) Vehicle control: 0.1% DMSO 
and 0.1% ethanol, 2) DMBA: 1µM DMBA [129,206] in DMSO and 0.1% ethanol, 3) 
1µM 4-hydroxytamoxifen (4HT): 0.1% DMSO and 1µM 4HT in ethanol, 4) 10µM 
4HT: 0.1% DMSO and 10µM 4HT, 5) DMBA+1µM 4HT and 6) DMBA+10µM 
4HT.  A drop of culture medium (approximately 10 µl) was placed to cover the ovary 
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 to prevent drying.    Ovaries were incubated at 37ºC with 5% CO2 and media were 
removed and fresh media and treatment were replaced every 2 days.  Following 1 
week of treatment, ovaries were collected, fixed in 4% PFA, and embedded in 
paraffin.  BSA, ascorbic acid, transferrin and penicillin-streptomycin were purchased 
from Sigma.  D-MEM/ F12 without phenol red and Albumax II were purchased from 
Invitrogen (Carlsbad, CA).  Millicell cell culture plate inserts (12mm, 0.4µm) were 
purchased from Millipore (Bedford, MA). 
 
Oocyte culture 
Sprague Dawley rats (4 weeks old) were superovulated with 20 IU of pregnant mare 
serum gonadotropin (PMSG) and human chorionic gonadotropin (hCG) 48 hours 
later.  Sixteen hours after hCG injection, cumulus-oocyte-complexes were collected 
from the oviducts and oocytes were denuded of cumulus cells in 1000 IU/ml 
hyaluronidase followed by 3 washes of Modified Rat Embryo Culture Medium 
(MRECM1) HEPES media [207,208].  Groups of 15-25 oocytes per treatment per 
replication (n=9 replication per treatment group) were cultured in 0.1 ml drops of 
culture medium containing 25mM NaHCO3, 0.5mM sodium pyruvate, 22mM 
HEPES, 0.5x Minimal Essential Medium Non-essential Amino acids (MEM NEAA), 
0.5x Minimal Essential Medium Essential Amino Acids (MEM EAA), 0.1mM 
GlutaMAX1, 110mM NaCl, 3.2mM KCl, 7.5mM D-glucose, 100µg/ml penicillin G 
K salt, 50µg/ml streptomycin sulfate, 13.53mM sodium lactate (60% syrup), 2mM 
CaCl2-2H2O and 0.5mM MgCl2-6H2O under sterile mineral oil.  Oocytes were 
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 incubated with the following treatment: 1) vehicle, 0.1% ethanol, 2) 40µM 4HT in 
ethanol, 3) 200nM doxorubicin (DOX) [208] + 0.1% ethanol, or 4) 200nM DOX+ 
40µM 4HT at 37ºC in a humidified atmosphere with 5% CO2 for 26 hours.   
 
Histological and morphological analysis 
Six-micron serial sections of ovaries from in vivo and organ culture experiments were 
deparaffinized, rehydrated, and stained with hematoxylin and eosin for histological 
analysis.  Follicles were classified as primordial (with one layer of flattened 
pregranulosa cells), primary (one expanded layer of cuboidal granulosa cells), pre-
antral (2-5 layers of granulosa cells), early antral, and late antral follicles and counted 
in every 10th section [209].  Only follicles with visible nuclei were used for 
enumeration.  The number of follicles in each category per ovary is expressed by the 
sum of counted follicle in every 10th section multiplied by 10.  Numbers of total 
follicles per ovary were estimated by summing up numbers of follicles of all 
categories.  Over 90% of all follicles in cultured postnatal day 4 ovaries were 
primordial follicles, thus, only this population was quantified [204].  At the end of the 
treatment period for oocyte cultures, morphological changes indicative of apoptosis 
or oocyte fragmentation were examined by a light microscope.   
 
Data analysis 
Data for follicular numeration are presented as the mean ± SEM and analyzed for 
main effects of DMBA or Cy and TAM, as well as their interaction on numbers of 
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 follicles using a one or two way ANOVA.  Results from oocyte cultures are presented 
as percent apoptosis, and analyzed using nonparametric Kruskal-Wallis.  Bonferroni 
analysis was used for multiple comparisons.  Differences are considered significant 
when p≤0.05.   
 
 
Results 
Tamoxifen rescued ovarian follicular loss caused by DMBA  
The mean number of total ovarian follicles per ovary in vehicle-treated controls was 
5.1x103.  Compared to controls, the higher dose of DMBA (10mg/wk) induced loss of 
total and primordial follicles (p < 0.05) while the lower dose of DMBA (5mg/wk) 
only induced significant total (p < 0.05) but not primordial follicle loss (p = 0.07, Fig. 
1 and 2).  Rats treated with TAM plus DMBA (both doses) inhibited DMBA-induced 
follicle loss and showed numbers of total and primordial follicles comparable to those 
of vehicle controls (Fig. 2).  Tamoxifen treatment alone caused an elevation in 
numbers of total and primordial follicles compared with vehicle controls (Fig. 2).  
Numbers of primary, pre-antral and early antral follicles were reduced by both doses 
of DMBA, while late antral follicle population was not affected by DMBA (Fig. 3).  
Tamoxifen caused a reduction in numbers of pre-antral and early antral follicles, and 
had no effect in primary and late antral population (Fig. 3).   
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 Tamoxifen inhibited Cy-induced follicular loss in the ovary 
The average number of total ovarian follicles in control animals was 8.1x103 per 
ovary. Both doses of Cy (35 and 50mg/kg/wk) induced a depletion in numbers of 
total and primordial follicles in comparison to controls (p < 0.05, Fig. 4 and 5) and 
had no effect on other follicle populations (Fig. 6).  The addition of tamoxifen 
inhibited Cy-induced follicular loss resulting in numbers of total and primordial 
follicles similar to vehicle controls (p < 0.05, Fig. 4 and 5).  Tamoxifen alone 
decreased the number of pre-antral follicles but had no effect in other follicle 
populations (Fig. 5 and 6). 
 
Protection against DMBA and DOX -induced ovotoxicity by tamxoifen is in part via 
local mechanisms 
One µM 4HT treatment alone induced moderate follicle loss in comparison with 
vehicle-treated ovaries (p < 0.05, Fig. 7).  DMBA induced even greater follicle loss in 
cultured ovaries (p < 0.05) compared to vehicle- and 4HT -treated ovaries (Fig. 7).  
Both 1 and 10 µM 4HT partially inhibited DMBA-induced toxicity (Fig. 7).  Results 
from oocyte culture showed that 12 and18% of oocytes exposed to vehicle and 4HT, 
respectively, underwent spontaneous fragmentation (Fig. 8 and 9).  Doxorubicin 
doubled (p < 0.05) the amount of fragmented oocytes compared with vehicle-treated 
controls, an effect that is alleviated by 4HT (p < 0.05, Fig. 8 and 9). 
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 Discussion 
Tamoxifen rescues ovarian follicular reserves from DMBA and Cy in vivo  
In the current study, we have shown that tamoxifen protects the ovary from the three 
most studied ovotoxicants, DMBA, Cy, and DOX.  In vivo, both 5 and 10 mg/kg 
DMBA depleted total ovarian follicles by 39% and 55%, respectively when compared 
to those of vehicle-treated animals.  Since over 80% of total ovarian follicles are 
primordial follicles, changes observed in numbers of total follicles often correlate 
with changes observed in those of primordial population.  TAM inhibited the loss of 
primordial follicles caused by both dosages of DMBA.  For pre-antral and early antral 
follicles, tamoxifen alone, DMBA alone and DMBA plus tamoxifen all decreased the 
number of these follicles.  Tamoxifen and other SERMs have been shown to induce 
anovulatory cysts and arrest follicle growth by triggering hypogonadoism [108] while 
DMBA has been shown to inactivate the ovary by inhibiting preovulatory 
gonadotropin secretion as well as promoting apoptosis in all follicles populations 
[128,210]. 
Like DMBA, a single treatment cycle of Cy reduced numbers of total follicles, 
and the addition of TAM inhibited the follicle loss.  Similar changes were observed in 
primordial follicle population.  Unlike DMBA, Cy does not affect the size of pre-
antral and early antral follicle populations when compared to controls.  This suggests 
a possible mechanism of action caused by Cy that directly targets primordial/primary 
follicles and promote cell death. 
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 Tamoxifen exerts its protection against DOX-induced oocyte fragmentation and 
DMBA-induced follicle loss in vitro 
In ovulated oocytes, doxorubicin increased the rate of fragmentation when compared 
to vehicle-treated controls and 4HT was able to antagonize this effect.  Studies have 
suggested that oocyte fragmentation in vitro occurs through apoptosis  [208]; 
therefore, a possible protective role of tamoxifen on DOX-treated oocytes may occur 
through inhibition of apoptosis.  When we investigated the effect of 4HT on ovarian 
histology in cultured ovaries exposed to DMBA, a moderate protective effect of 
tamoxifen was observed in endangered ovarian follicles.  4HT alone in culture 
moderately reduced the number of follicles when compared to vehicle controls.  This 
observation is not consistent with results from the in vivo study in which TAM did 
not have any ovotoxic effect, and this may be explained by the serum-free and 
hormone-free culture medium that the ovary was exposed to in culture, differing from 
the physiological environment.  DMBA further depleted the number of follicles by 
66% in comparison to that of control ovaries and the combination of DMBA and 4HT 
partially inhibited this loss resulting in similar follicle numbers in 4HT and 
DMBA+4HT-treated ovaries.  Together, our results suggest that the optimal effects of 
tamoxifen on protecting the ovary from ovotoxic insults are likely to be through local 
plus systemic mechanisms. 
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 Effects of tamoxifen on reproductive endocrinology of cancer patients undergoing 
chemotherapy 
Tamoxifen is a commonly used drug in cancer patients and the subject of many 
clinical and preclinical trials [157,165,211], and adjuvant tamoxifen therapy has 
already been used in premenopausal female cancer patients without adverse side 
effects [199,201].  However, past studies have overlooked changes in the ovary and 
have been inappropriate in design, treatment duration, patient age and endpoints to 
address fertility.  Interestingly, a study by Rose and Davis conducted in 1980 to 
examine reproductive endocrinology during treatment in premenopausal breast cancer 
patients receiving cyclophosphamide + methotrexate + 5-fluorouracil (CMF) 
chemotherapy with or without simultaneous prednisone or prednisone + tamoxifen 
showed similar results to that in our study [109].  While the clinical study did not 
directly measure markers of follicular reserve or reproductive function post-treatment, 
Rose and Davis revealed that the addition of tamoxifen to the regimen was associated 
with elevated estradiol, decreased FSH concentrations and delayed iatrogenic 
amenorrhea during 6 and 10 months of treatment [109].  This observation suggests 
protection of ovarian function provided by tamoxifen in patients undergoing 
chemotherapy. 
 
Possible mechanisms by which tamoxifen protects ovarian follicular reserves 
The mechanism by which tamoxifen acts to rescue ovarian follicles is unclear and 
needs further investigation.  Systemically, tamoxifen may cause effects similar to 
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 GnRH agonist by disrupting the hypothalamic-pituitary-ovarian axis [195], therefore, 
protecting the ovary by keeping it a quiescent anovulatory state.  Similar observations 
have also been reported in rats treated with another SERM, raloxifene [108].  The 
advantage of tamoxifen over GnRH agonist for the protection of the ovary may be the 
addition of local beneficial effect exerted by tamoxifen.  Locally, the role of 
tamoxifen, whether estrogenic or anti-estrogenic, in the ovary has not been clarified 
due to the cellular complexity of the ovary.  Interestingly, E2 has been shown by our 
group (unpublished data) and others to provide protection against chemical-induced 
ovarian follicle loss in the rat [212]; however, clinically, E2 treatment in 
premenopausal women is dangerous and tumorigenic in several tissues and is 
therefore unpractical for therapeutic usage [213].  Premenopausal women taking 
SERMs including tamoxifen have been shown to have slightly increased E2 
production in the ovary due to a compensatory mechanism suggesting an estrogenic 
role of tamoxifen in the ovary [57].  In addition, tamoxifen can act as an anti-oxidant 
which is associated with cell survival and affects the retinoic acid pathway that is also 
important for cell survival [214], although the potentiation of cancer cytotoxicity by 
tamoxifen in past studies argues against the primacy of such general mechanisms 
during ovarian protection.   
In conclusion, we have shown in the current study that tamoxifen rescues 
ovarian follicular reserves from the ovotoxic chemical DMBA and the chemotherapy 
drugs Cy and DOX.  The only currently approved option for fertility preservation 
following chemotherapy is cryopreservation of the embryo.  This method does not 
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 prevent ovarian toxicity from cancer therapy and premature menopause remains a 
problem even in women with cancer actively seeking fertility preservation.   
Tamoxifen may serve as a better candidate drug for translation to fertility 
preservation in several ways: 1) tamoxifen-related side effects including menopausal-
like symptoms and impairment of the hypothalamus-gonadal axis are reversible 
following the discontinuation of tamoxifen, 2) tamoxifen has a long and extensive 
safety record in the cancer patient population, 3) the use of tamoxifen for fertility 
preservation offers clear advantages in cost, convenience and efficacy over current 
options, 4) tamoxifen administered concurrently with chemotherapy appears to have 
no negative effect on cancer progression and has been suggested to alleviate 
chemotherapy resistance in preclinical studies.   
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Figure 1: H&E sections of the ovary from rats exposed to vehicle (CONT, a), DMBA 
(10mg/wk, b), tamoxifen (TAM, c), or DMBA + TAM (d) for 2 weeks.  Arrows = 
primordial follicles.  DMBA decreased follicular reserves in the ovary compared with 
vehicle-treated controls and the addition of tamoxifen inhibited this depletion.  
Tamoxifen alone elevated the number of follicles in the ovary compared with vehicle-
treated controls.
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Figure 2: Numbers of follicle loss relative to vehicle-treated controls for total 
(follicles at all developmental stages, upper panel) and primordial (bottom panel) 
follicle populations.  Average number of follicles per ovary in vehicle-treated controls 
was 5.1x103.  DMBA treatment at 5 and 10 mg/wk induced follicles loss compared 
with controls and the addition of tamoxifen (TAM) to both doses of DMBA inhibited 
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 this depletion.  TAM alone elevated total follicle numbers in comparison with vehicle 
controls.  Different letters indicate significant differences among different treatment 
groups. 
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Figure 3: Numbers of follicle loss relative to vehicle-treated controls for primary, 
pre-antral, early antral and late antral follicles remaining in the ovary of rats treated 
with vehicle, tamoxifen (TAM), DMBA (5 or 10 mg/wk) or DMBA+TAM.  Average 
numbers of follicles per ovary in vehicle-treated controls were 0.87x103, 0.47x103, 
0.19x103 and 0.035x103 for primary, pre-antral, early antral and late antral follicle 
populations, respectively.  In primary follicles, DMBA treatment at 10 mg/wk 
induced follicles loss compared with vehicle controls and the addition of TAM to 10 
mg/wk DMBA inhibited this depletion.  TAM alone did not affect primary follicle 
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 numbers.  For pre-antral and early antral follicle populations, DMBA at both doses, 
TAM, and DMBA+TAM all induced a loss of follicles.  Different letters indicate 
significant differences among different treatment groups. 
 95
  
 
Figure 4: H&E sections of the ovary from rats exposed to vehicle (CONT, a), 
cyclophosphamide (Cy, 50mg/kg, b), tamoxifen (TAM, c), or Cy + TAM (d) for 4 
weeks.  Arrows = primordial and primary follicles.  Cy decreased total numbers of 
follicles in the ovary compared with vehicle-treated controls and the addition of 
tamoxifen inhibited this depletion.  TAM did not affect the number of follicles in the 
ovary compared with vehicle-treated controls. 
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Figure 5: Numbers of follicle loss relative to vehicle-treated controls for total 
(follicles at all developmental stages, upper panel) and primordial (bottom panel) 
follicle populations.  Average number of follicles per ovary in vehicle-treated controls 
was 6.1x103.  Cyclophosphamide (Cy) treatment at 35 and 50 mg/kg/wk induced 
follicles loss compared with controls and the addition of TAM to both doses of Cy 
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 inhibited this depletion.  TAM alone did not affect follicle numbers.  Different letters 
indicate significant differences among different treatment groups.
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Figure 6: Numbers of follicle loss relative to vehicle-treated controls for primary, 
pre-antral, early antral and late antral follicles remaining in the ovary of rats treated 
with vehicle, tamoxifen (TAM), Cy (35 or 50 mg/kg/wk) or Cy+TAM.  Average 
numbers of follicles per ovary in vehicle-treated controls were 1.1x103, 0.70x103, 
0.22x103 and 0.017x103 for primary, pre-antral, early antral and late antral follicle 
populations, respectively.  In pre-antral follicles, TAM and Cy+TAM induced follicle 
loss compared with vehicle controls while Cy alone did not affect follicle numbers.  
Follicles of primary, early antral and late antral did not show a treatment-dependent 
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 effect in their numbers. Different letters indicate significant differences among 
different treatment groups. 
 
 100
  
 
 
Figure 7: Numbers of primordial follicle loss relative to vehicle-treated controls in 
ovaries exposed to vehicle (CON), 4-hydroxytamoxifen (1 or 10 µM 4HT), DMBA or 
DMBA+TAM.  DMBA induced follicle loss compared with controls and the addition 
of tamoxifen at both doses inhibited this depletion.  Tamoxifen at 1 µM elevated the 
number of lost follicles while 10 µM did not affect follicle numbers.  Different letters 
indicate significant differences among different treatment groups. 
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Figure 8: Mature oocytes exposed to vehicle (a), 4-hydroxytamoxifen (4HT, b), 
doxorubicin (DOX, c), or DOX+4HT (d) for 26 hours.  Healthy oocytes surround by 
zona pellucida were observed after vehicle and 4HT treatment (a, b).  Doxorubicin 
induces fragmentation in cultured oocytes (c), an effect that is antagonized by the 
addition of 4HT (d). 
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Figure 9: Quantitative analysis of the percentage of oocytes undergoing 
fragmentation.  Oocytes incubated with doxorubicin (DOX) showed increased 
fragmentation rate compared with vehicle-treated controls.  This elevated 
fragmentation rate was inhibited by the addition of 4-hydroxytamoxifen.  The total 
number of oocytes cultured in each treatment group is indicated in parentheses inside 
the respective bar.  * indicates a significant difference in comparison to vehicle-
treated controls.
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CHAPTER V 
 
 
 
OVERALL CONCLUSION AND DISCUSSION 
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 Feasibility and rationale for dual cancer prevention: 
To overcome the difficulties of ovarian cancer prevention, our laboratory proposed a 
strategy that prevents breast and ovarian cancer simultaneously.  This novel idea 
takes advantage of the fact that women at elevated risk for breast cancer are often also 
at elevated risk for ovarian cancer suggesting intertwined etiologies and possible 
common prevention targets.  We developed a rat model that exhibits concurrent 
mammary and ovarian cancer and used this to screen drug candidates that may 
decrease risks for both cancers.  Although the effects of chemoprevention drugs can 
be tested separately in preclinical models, this approach ignores the intertwined 
etiologies of breast and ovarian cancer as well as potential synergism between effects 
in the breast and ovary of prevention drugs.  Our data showed for the first time that 
the combination of systemic E2 and local ovarian application of DMBA induced 
mammary and ovarian cancer simultaneously and effectively in the rat [171].  This 
model produced 100% mammary preneoplasia/ neoplasia and 50% ovarian 
preneoplasia following 6 months of treatment.   
 
Tamoxifen is not suitable as a dual cancer prevention therapy for breast and 
ovarian cancer, however, it does not accelerate ovarian cancer progression:   
Clinically, tamoxifen was first approved by the FDA as a contraceptive agent in the 
1970s, but this application was later abandoned.  Currently, tamoxifen is used to treat 
hormonal-responsive breast cancer, to reduce breast cancer risk and is currently the 
most prescribed cancer drug worldwide [165].  However, the effect of tamoxifen on 
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 ovarian cancer risk is still unclear.  In premenopausal women, tamoxifen and other 
SERMs have been shown to promote abnormal ovarian function and cystic changes 
(follicular) in the ovary; therefore, many researchers have suggested that the use of 
tamoxifen may be associated with increased risk for ovarian cancer [32,33,57,58].  
Using the dual cancer model, we showed that tamoxifen, while preventing mammary 
carcinogenesis, did not retard ovarian cancer progression indicating that tamoxifen is 
not suitable for use as a simultaneous prevention agent to reduce risks of both breast 
and ovarian cancer [196].  Interestingly, tamoxifen did not accelerate the progression 
towards ovarian cancer in this model supporting the safety of the use of tamoxifen to 
reduce breast cancer risk in a population that are very likely to predispose to elevated 
ovarian cancer risk [196].       
 
Other drug candidates that may simultaneously prevent breast and ovarian cancer:   
In the future, our dual cancer model will continue to be used for the screening of drug 
candidates that may simultaneously decrease breast and ovarian cancer risks.  One 
potential candidate that may soon be tested for its dual prevention efficacy is 
letrozole, an aromatase inhibitor.  Aromatase is responsible for the majority of 
estrogen synthesis and estrogen plays a critical role in both breast and ovarian 
carcinogenesis.  In addition, prolonged use of hormone replacement therapy is 
associated with increased breast as well as ovarian cancer risk [215-217].  While 
tamoxifen partially antagonizes estrogen’s action by working at the level of receptors, 
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 aromatase inhibitors, on the other hand, block estrogen production and may offer the 
best efficacy of hormonal responsive breast and ovarian cancer prevention [218].  
Results from the IBIS-II (International Breast Cancer Intervention Study) trial 
have confirmed the efficacy of aromatase inhibitors in preventing breast cancer in 
postmenopausal women, with fewer undesirable side effects such as endometrial 
cancer or thromboembolic events caused by the use of tamoxifen [219,220].  
Aromatase inhibitors have been associated with bone density loss and fracture from 
profound estrogen depletion. However, these symptoms are usually manageable with 
supplemental hormones and biophosphonates [221].  The potential of using aromatase 
inhibitors to prevent ovarian cancer while not clear, is supported by studies showing 
their ability to sensitize ovarian tumor cells to chemotherapy and prevent recurrent 
ovarian cancer [222].  
In our studies, tamoxifen did not prevent ovarian cancer progression and is 
therefore not suitable for dual cancer prevention.  Letrozole, based on its mechanism 
of action, may serve as a plausible candidate to lower risks for both breast and 
ovarian cancer.  The potential efficacy of letrozole to prevent both cancers should be 
tested using our dual cancer model.  
 
The use of tamoxifen to preserve fertility in premenopausal women undergoing 
cytotoxic chemotherapy treatment regimen:   
While examining the ovary of our dual cancer model treated with tamoxifen, we 
serendipitously discovered a novel protective effect of tamoxifen against DMBA-
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 induced follicle loss in the ovary.  From several follow-up studies, we were able to 
show for the first time that tamoxifen inhibits DMBA, cyclophosphamide and 
doxorubicin-induced ovotoxicity in the rat.  These results suggest a potential 
therapeutic intervention with tamoxifen to preserve fertility in premenopausal women 
undergoing chemotherapy.  Currently, the only established fertility preservation 
method for women undergoing chemotherapy is embryo cryopreservation.  This 
method is expensive, invasive, and requires a partner and, more importantly, it 
requires a delay in cancer treatment by several weeks to months.   
One experimental protocol is the use of GnRH agonists to protect the ovary 
against chemotherapy-induced toxicity by disrupting hypothalamic-pituitary-ovarian 
axis and suppressing ovarian function [223].  GnRH agonists have been shown to be 
effective in rodents and non-human primates [122], but its efficacy to protect the 
ovary in women undergoing chemotherapy is still controversial [125,224].  In 
contrast to GnRH agonist-induced systemic hypogonadism which was ineffective in 
human trials to preserve fertility, our results demonstrated that tamoxifen seems to 
protect the ovary in part through local mechanisms suggesting an alternative action by 
tamoxifen to protect ovarian follicles.   
 
Possible mechanisms of action by which tamoxifen inhibit environmental toxicant- 
and chemotherapy-induced follicle loss:   
The mechanism responsible for the protective effect of tamoxifen when rescuing 
ovarian follicles from DMBA and cyclophosphamide-induced toxicity is still unclear 
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 and needs further investigation.  We speculate that the observed results may be a 
combined effect of local and systemic actions induced by tamoxifen.  Systemically, 
tamoxifen may act similarly to GnRH agonists, inactivating normal ovarian function 
and therefore preserving a quiescent follicular reserve.  Locally, tamoxifen may 
prevent toxicant-induced follicular loss by inhibiting follicular apoptosis and 
disrupting drug transfer into the ovary.   
Apoptosis-driven ovarian damage has been thought to play a critical role in 
oocyte destruction and premature ovarian failure caused by environmental toxicants 
and chemotherapy [129,225-227].  Chemotherapy induces elevated levels of pro-
apoptotic molecules such as caspase-2/3 and Bax, and decreased levels of the anti-
apoptotic marker Bcl-2 in ovarian follicles [228,229].  Interestingly, E2 has been 
shown to protect against 4-vinylcyclohexene diepoxide-induced follicle loss in the 
ovary due to anti-oxidant and anti-apoptosis properties including decreasing levels of 
caspase-3 [212].  Of course, E2 is tumorigenic in several tissues and the use of E2 to 
preserve fertility in cancer patients is unfeasible.  Tamoxifen, when it promotes 
selective estrogenic actions, also has anti-oxidant properties that contribute to the 
protective effect of tamoxifen in the cardiovascular system [214,230].  Therefore, 
tamoxifen may promote estrogen-like actions in ovarian follicles and offer similar 
protection against cyclophosphamide-induced ovotoxicity without the carcinogenic 
effect of E2 in women.  In addition, tamoxifen has been shown to alter levels of 
aldehyde dehydrogenase, an enzyme that is responsible for the conversion of retinol 
to retinoic acid [231].  Retinoic acid has been identified as a potent survival factor for 
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 female germ cells in rodents [232].  Tamoxifen may therefore promote survival of 
oocytes and prevent chemotherapy-induced follicle loss by affecting the retinoic acid 
pathway coupled with estrogenic anti-oxidant effects, in a tissue specific manner.     
Tamoxifen may also protect the ovary by inhibiting drug transfer to the ovary.  
Cyclophosphamide is a prodrug that is metabolized to active 4-
hydroxycyclophosphamide (4HC) by hepatic CYP enzymes; therefore, it can not be 
metabolized in the ovary and the only route for its active metabolite’s delivery to the 
ovary is via blood supply [233].  Tamoxifen may suppress normal ovarian function 
and the lack of folliculogenesis may lead to diminished blood flow to the ovary 
resulting in local hypoxia and decreased 4HC accumulation in the ovary [234].  
Tamoxifen may also inhibit toxicant accumulation in the ovary by altering levels of 
p-glycoprotein.  P-glycoprotein is a membrane pump located in the wall of ovarian 
capillaries and is responsible for detoxification and steroid transport [235].  In cancer 
cells, p-glycoprotein is responsible for pumping chemotherapy drugs out of the cell 
and causes multi-drug resistance [236].  Tamoxifen has been shown in preclinical and 
in vitro studies to down regulate p-glycoprotein and reverse this phenotype assuming 
that down regulation of p-glycoprotein is associated with decreased exposure to 
chemotherapy [201,237,238].  In addition, tamoxifen may inhibit drug transfer to the 
oocyte by moderating the expression of gap junctions such as connexin 43 and 37.  
Connexin 43 and 37 form granulosa-to-granulosa and granulosa-to-oocyte 
communications, respectively, and are essential for follicular survival and 
development [239,240].  A reduction in the expression of these gap junctions may 
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 interrupt drug transport into the oocyte resulting in decreased drug accumulation in 
these cells.  Elucidation of the mechanism responsible for tamoxifen protection of 
ovarian follicles will be crucial to development of novel strategies for fertility 
preservation following chemotherapy in females. 
 
Radiation-induced ovotoxicity:   
Both chemotherapy and radiation therapy destroy ovarian follicles and cause 
premature reproductive aging.  Whether tamoxifen can also protect ovarian follicles 
from radiation-induced damage is likely to be dependent upon tamoxifen’s 
mechanism of action.  If tamoxifen protects ovarian follicles only by suppressing 
ovarian function and keeping primordial follicles quiescent, radiation therapy while 
less effectively will still damage DNA in oocytes and granulosa cells directly and 
cause follicular death.  If tamoxifen rescues ovarian follicles by altering cell-to-cell 
communication within a follicle, or expression of membrane pumps responsible for 
cyclophosphamide transport, it may still fail to protect follicles from radiation-
induced injury.   
However, if tamoxifen reduces blood flow to the ovary, therefore reducing 
local oxygen concentrations, it may be able to weaken radiation-induced ovarian 
damage in comparison to ovaries under normal oxygen conditions.  Oxygen is a 
potent radiosensitizer that increases the effectiveness of a given dose of radiation by 
forming DNA-damaging free radicals [241,242].  Studies have shown that tumor cells 
in a hypoxic environment are more resistant to radiation damage than those in a 
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 normal oxygen environment [243,244].  Alternatively, if tamoxifen protects ovarian 
follicles by inhibiting apoptosis, while not blocking radiation-induced DNA damage, 
it may allow additional DNA repair mechanisms to take place and fix the damaged 
DNA [245-247].  However, if this happens, the integrity of the germline DNA 
following repair will need to be examined carefully. 
 
Safety issues of using tamoxifen as fertility preservation treatment:   
Tamoxifen has been prescribed to patients with hormonal responsive breast cancer for 
the past 30 years and has a very extensive safety record [211,248].  The 
recommended continuous use of tamoxifen (20mg/day) has been limited to 5 years 
due to the adverse side effects (i.e. blood clots, stroke, and uterine cancer) observed 
with longer usage [165].    Typical chemotherapy regimens, such as CMF 
(cyclophosphamide + methotrexate + 5-fluorouracil) and CHOP (cyclophosphamide 
+ doxorubicin + prednisone + vincristine) are usually given in cycles over a period of 
3-6 months.  Results from our studies suggest that a concurrent administration of 
tamoxifen with cytotoxic chemotherapy for the duration of the chemotherapy regimen 
will protect ovarian follicles from destruction and therefore preserve fertility.  In 
premenopausal women, short term (<2 years) tamoxifen has been shown to induce 
menopausal symptoms and irregular menstruation, and these symptoms are reversible 
upon drug withdrawal.   
Furthermore, a major concern of the use of any adjuvant treatment is its 
potential to counteract or interfere with the efficacy of standard chemotherapy.  
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 Tamoxifen has actually been suggested to increase the efficacy of chemotherapy in 
animal models due to the ability of tamoxifen to downregulate p-glycoprotein, a 
membrane transporter that is responsible for multi-drug resistant phenotype in cancer 
cells.  This potential effect of tamoxifen was tested in phase III trials without 
establishing such benefit [201], nonetheless, results from these trials showed that 
even high dose tamoxifen has little effect on the toxicities and pharmacokinetics of 
standard cancer chemotherapy. 
 
Translational use of tamoxifen for fertility preservation; from bench side to 
bedside:   
Results from our studies suggest a novel use of tamoxifen for fertility preservation in 
premenopausal women undergoing cancer chemotherapy.  While tamoxifen has been 
used for cancer treatment for more than 3 decades and has been safely tested as 
concurrent cancer treatment, past human studies focused on older women and ignored 
any reproductive endpoints.  The translation of this preclinical research into clinical 
trials should be facilitated by the established use and safety of tamoxifen with and 
without standard chemotherapy.  This novel approach for the use of tamoxifen in 
preserving fertility can also be easily tested by adding reproductive endpoints (serum 
hormone concentrations, regularity of menstrual cycle, ability to conceive) to existing 
clinical trials testing the effect of tamoxifen as adjuvant chemotherapy in young 
female patients undergoing cytotoxic cancer therapy. 
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 More than 100,000 women under the age of 45 are diagnosed with cancer 
each year in the United States and 50-80% of these patients that receive cytotoxic 
chemotherapy suffer from premature ovarian failure and infertility.  Previously, this 
infertility and iatrogenic menopause was viewed by physicians and patients as an 
acceptable cost of curative chemotherapy and radiation regimens.  However, with 
early diagnosis and as more women survive their cancers and strive to resume normal 
family life, cancer therapy-induced infertility has become a major survivorship issue.  
Our result, for the first time, showed that tamoxifen prevents chemotherapy-induced 
follicle destruction and may offer a dramatic clinical benefit to preserve fertility in 
young female patients undergoing chemotherapy or even radiation therapy.   
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